COSTIMULATORY CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING IL13R-alpha-2

Abstract

Chimeric transmembrane immunoreceptors (CAR) which include an extracellular domain that includes IL-13 or a variant thereof that binds interleukin-13R.alpha.2 (IL13R.alpha.2), a transmembrane region, a costimulatory domain and an intracellular signaling domain are described.

Description

CLAIM OF PRIORITY

[0001] This application claims priority under 35 U.S.C. .sctn. 120 to U.S. patent application Ser. No. 15/167,869, filed on May 27, 2016, which claims priority under 35 U.S.C. .sctn. 365(c) to International Patent Application PCT/US2015/051089, filed on Sep. 18, 2015, which claims priority under 35 U.S.C. .sctn. 119(e) to provisional U.S. Patent Application 62/053,068, filed on Sep. 19, 2014, the entire contents of each which are hereby incorporated by reference.

BACKGROUND

[0002] Tumor-specific T cell based immunotherapies, including therapies employing engineered T cells, have been investigated for anti-tumor treatment. In some cases the T cells used in such therapies do not remain active in vivo for a long enough period. In some cases, the tumor-specificity of the T cells is relatively low. Therefore, there is a need in the art for tumor-specific cancer therapies with longer term anti-tumor functioning.

[0003] Malignant gliomas (MG), which include anaplastic astrocytoma (AA-grade III) and glioblastoma (GBM-grade IV), have an incidence rate of approximately 20,000 new cases diagnosed annually in the United States. According to the American Brain Tumor Association total prevalence of individuals living with a malignant brain tumor, based on United States 2010 census data, is roughly 140,000 persons. Although MG is a rare disease, it is highly aggressive and heterogeneous with respect to its malignant behavior and nearly uniformly lethal. Current standard-of-care therapies for high-grade MG yield only short term benefits, and these brain tumors are virtually incurable. Indeed, even with modern surgical and radiotherapeutic techniques, which often exacerbate the already severe morbidities imposed by location in the central nervous system (CNS), the 5-year survival rates are quite low. Furthermore, for the majority of patients who relapse with disease, there are few therapeutic options. Thus, there is a significant need for more effective therapies, particularly for those patients that have recurred/progressed following frontline therapies, and participation of this patient population in clinical trials is warranted.

[0004] Adoptive T cell therapy (ACT) utilizing chimeric antigen receptor (CAR) engineered T cells may provide a safe and effective way to reduce recurrence rates of MG, since CAR T cells can be engineered to specifically recognize antigenically-distinct tumor populations (Cartellieri et al. 2010 J Biomed Biotechnol 2010:956304; Ahmed et al. 2010 Clin Cancer Res 16:474; Sampson et al. 2014 Clin Cancer Res 20:972; Brown et al. 2013 Clin Cancer Res 2012 18:2199; Chow et al. 2013 Mol Ther 21:629), and T cells can migrate through the brain parenchyma to target and kill infiltrative malignant cells (Hong et al. 2010 Clin Cancer Res 16:4892; Brown et al. 2007 J Immunol 179:3332; Hong et al. 2010 Clin Cancer Res 16:4892; Yaghoubi 2009 Nat Clin PRact Oncol 6:53). Preclinical studies have demonstrated that IL13R.alpha.2-targeting CAR+ T cells exhibit potent major histocompatibility complex (MHC)-independent, IL13R.alpha.2-specific cytolytic activity against both stem-like and differentiated glioma cells, and induce regression of established glioma xenografts in vivo (Kahlon et al. 2004 Cancer Res 64:9160; Brown et al. 2012 Clin Cancer Res 18:2199).

SUMMARY

[0005] Described herein are chimeric transmembrane immunoreceptors (chimeric antigen receptors or "CARs") which comprise an extracellular domain, a transmembrane region and an intracellular signaling domain. The extracellular domain is made up of an IL-13 ligand that binds interleukin-13R.alpha.2 (IL13R.alpha.2) and, optionally, a spacer, comprising, for example a portion human Fc domain. The transmembrane portion includes a CD4 transmembrane domain, a CD8 transmembrane domain, a CD28 transmembrane domain, a CD3 transmembrane domain or a 4IBB transmembrane domain. The intracellular signaling domain includes the signaling domain from the zeta chain of the human CD3 complex (CD3.zeta.) and one or more costimulatory domains, e.g., a 4-1BB costimulatory domain. The extracellular domain enables the CAR, when expressed on the surface of a T cell, to direct T cell activity to those cells expressing IL13R.alpha.2, a receptor expressed on the surface of tumor cells, including glioma. Importantly, the IL13R.alpha.2 binding portion of the CAR includes an amino acid modification, such as an E13Y mutation, that increases binding specificity. The inclusion of a costimulatory domain, such as the 4-1BB (CD137) costimulatory domain in series with CD3 in the intracellular region enables the T cell to receive co-stimulatory signals. T cells, for example, patient-specific, autologous T cells can be engineered to express the CARs described herein and the engineered cells can be expanded and used in ACT. Various T cell subsets can be used. In addition, the CAR can be expressed in other immune cells such as NK cells. Where a patient is treated with an immune cell expressing a CAR described herein the cell can be an autologous or allogenic T cell. In some cases the cells used are CD4+ and CD8+ central memory T cells (T.sub.CM), which are CD45RO+CD62L+, and the use of such cells can improve long-term persistence of the cells after adoptive transfer compared to the use of other types of patient-specific T cells.

[0006] Described herein is a nucleic acid molecule encoding a chimeric antigen receptor (CAR)r, wherein the chimeric antigen receptor comprises: human IL-13 or a variant thereof having 1-10 (e.g., 1 or 2) amino acid modifications; a transmembrane domain selected from: a CD4 transmembrane domain or variant thereof having 1-10 (e.g., 1 or 2) amino acid modifications, a CD8 transmembrane domain or variant thereof having 1-10 (e.g., 1 or 2) amino acid modifications, a CD28 transmembrane domain or a variant thereof having 1-10 (e.g., 1 or 2) amino acid modifications, and a CD3 transmembrane domain or a variant thereof having 1-10 (e.g., 1 or 2) amino acid modifications; a costimulatory domain; and CD3 .zeta. signaling domain of a variant thereof having 1-10 (e.g., 1 or 2) amino acid modifications.

[0007] In various embodiments the costimulatory domain is selected from the group consisting of: a CD28 costimulatory domain or a variant thereof having 1-10 (e.g., 1 or 2) amino acid modifications, a 4-IBB costimulatory domain or a variant thereof having 1-10 (e.g., 1 or 2) amino acid modifications and an OX40 costimulatory domain or a variant thereof having 1-10 (e.g., 1 or 2) amino acid modifications. In certain embodiments, a 4IBB costimulatory domain or a variant thereof having 1-10 (e.g., 1 or 2) amino acid modifications in present.

[0008] Additional embodiment the CAR comprises: a variant of a human IL13 having 1-10 amino acid modification that increase binding specificity for IL13R.alpha.2 versus IL13R.alpha.1; the human IL-13 or variant thereof is an IL-13 variant comprising the amino acid sequence of SEQ ID NO:3 with 1 to 5 amino acid modifications, provided that the amino acid at position 11 of SEQ ID NO:3 other than E; two different costimulatory domains selected from the group consisting of: a CD28 costimulatory domain or a variant thereof having 1-10 (e.g., 1 or 2) amino acid modifications, a 4IBB costimulatory domain or a variant thereof having 1-10 (e.g., 1 or 2) amino acid modifications and an OX40 costimulatory domain or a variant thereof having 1-10 (e.g., 1 or 2) amino acid modifications; two different costimulatory domains selected from the group consisting of: a CD28 costimulatory domain or a variant thereof having 1-2 amino acid modifications, a 4IBB costimulatory domain or a variant thereof having 1-2 amino acid modifications and an OX40 costimulatory domain or a variant thereof having 1-2 amino acid modifications; human IL-13 or a variant thereof having 1-2 amino acid modifications; a transmembrane domain selected from: a CD4 transmembrane domain or variant thereof having 1-2 amino acid modifications, a CD8 transmembrane domain or variant thereof having 1-2 amino acid modifications, a CD28 transmembrane domain or a variant thereof having 1-2 amino acid modifications, and a CD3.zeta. transmembrane domain or a variant thereof having 1-2 amino acid modifications; a costimulatory domain; and CD3.zeta. signaling domain of a variant thereof having 1-2 amino acid modifications; a spacer region located between the IL-13 or variant thereof and the transmembrane domain (e.g., the spacer region comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 4, 14-20, 50 and 52); the spacer comprises an IgG hinge region; the spacer region comprises 10-150 amino acids; the 4-1BB signaling domain comprises the amino acid sequence of SEQ ID NO:6; the CD3.zeta. signaling domain comprises the amino acid sequence of SEQ ID NO:7; and a linker of 3 to 15 amino acids that is located between the costimulatory domain and the CD3 .zeta. signaling domain or variant thereof. In certain embodiments where there are two costimulatory domains, one is an 4-IBB costimulatory domain and the other a costimulatory domain selected from: CD28 and CD28gg

[0009] In some embodiments: nucleic acid molecule expresses a polypeptide comprising an amino acid sequence selected from SEQ ID NOs: 10, 31-48 and 52; the chimeric antigen receptor comprises a IL-13/IgG4/CD4t/41-BB region comprising the amino acid of SEQ ID NO:11 and a CD3 .zeta. signaling domain comprising the amino acid sequence of SEQ ID NO:7; and the chimeric antigen receptor comprises the amino acid sequence of SEQ ID NOs: 10, 31-48 and 52.

[0010] Also disclosed is a population of human T cells transduced by a vector comprising an expression cassette encoding a chimeric antigen receptor, wherein chimeric antigen receptor comprises: human IL-13 or a variant thereof having 1-10 amino acid modifications; a transmembrane domain selected from: a CD4 transmembrane domain or variant thereof having 1-10 amino acid modifications, a CD8 transmembrane domain or variant thereof having 1-10 amino acid modifications, a CD28 transmembrane domain or a variant thereof having 1-10 amino acid modifications, and a CD3.zeta. transmembrane domain or a variant thereof having 1-10 amino acid modifications; a costimulatory domain; and CD3 .zeta. signaling domain of a variant thereof having 1-10 amino acid modifications. In various embodiments: the population of human T cells comprise a vector expressing a chimeric antigen receptor comprising an amino acid sequence selected from SEQ ID NOs: 10, 31-48 and 52; the population of human T cells are comprises of central memory T cells (Tcm cells) (e.g., at least 20%, 30%, 40%, 50% 60%, 70%, 80% of the cells are Tcm cells; at least 15%, 20%, 25%, 30%, 35% of the Tcm cells are CD4+ and at least 15%, 20%, 25%, 30%, 35% of the Tcm cells are CD8+ cells).

[0011] Also described is a method of treating cancer in a patient comprising administering a population of autologous or allogeneic human T cells (e.g., autologous or allogenic T cells comprising Tcm cells, e.g., at least 20%, 30%, 40%, 50% 60%, 70%, 80% of the cells are Tcm cells; at least 15%, 20%, 25%, 30%, 35% of the Tcm cells are CD4+ and at least 15%, 20%, 25%, 30%, 35% of the Tcm cells are CD8+ cells) transduced by a vector comprising an expression cassette encoding a chimeric antigen receptor, wherein chimeric antigen receptor comprises an amino acid sequence selected from SEQ ID NOs: 10, 31-48 and 52. In various embodiments: the population of human T cells comprise central memory T cells; the cancer is glioblastoma; and the transduced human T cells where prepared by a method comprising obtaining T cells from the patient, treating the T cells to isolate central memory T cells, and transducing at least a portion of the central memory cells to with a viral vector comprising an expression cassette encoding a chimeric antigen receptor, wherein chimeric antigen receptor comprises an amino acid sequence selected from SEQ ID NOs: 10, 31-48 and 52.

[0012] Also described is: a nucleic acid molecule encoding an polypeptide comprising an amino acid sequence that is at least 95% identical to an amino acid sequence selected from SEQ ID NO:10 and SEQ ID NOs: 10, 31-48 and 52; a nucleic acid molecule encoding an polypeptide comprising an amino acid sequence that is identical to an amino acid sequence selected from SEQ ID NO: 10, 31-48 and 52 except for the presence of no more than 5 amino acid substitutions, deletions or insertions; a nucleic acid molecule encoding an polypeptide comprising an amino acid sequence that is identical to an amino acid sequence selected from SEQ ID NO:10 and SEQ ID NOs: 10, 31-48 and 52 except for the presence of no more than 5 amino acid substitutions; and a nucleic acid molecule encoding an polypeptide comprising an amino acid sequence that is identical to an amino acid sequence selected from SEQ ID NO:10 and SEQ ID NOs: 10, 31-48 and 52 except for the presence of no more than 2 amino acid substitutions.

[0013] Certain CAR described herein, for example, the IL13(EQ)BB.zeta.CAR and the IL13(EQ)CD28-BB.zeta. CAR, have certain beneficial characteristics compared to certain other IL13-targeted CAR. For example, they have improved selectivity for IL13R.alpha., elicit lower Th2 cytokine production, particularly lower IL13 production.

[0014] T cells expressing a CAR targeting IL13R.alpha.2 can be useful in treatment of cancers such as glioblastoma, as well as other cancer that expresses IL13R.alpha.2 which include but are not limited to medulloblastoma, breast cancer, head and neck cancer, kidney cancer, ovarian cancer and Kaposi's sarcoma. Thus, this disclosure includes methods for treating cancer using T cells expressing a CAR described herein.

[0015] This disclosure also nucleic acid molecules that encode any of the CARs described herein (e.g., vectors that include a nucleic acid sequence encoding one of the CARs) and isolated T lymphocytes that express any of the CARs described herein.

[0016] The CAR described herein can include a spacer region located between the IL13 domain and the transmembrane domain. A variety of different spacers can be used. Some of them include at least portion of a human Fc region, for example a hinge portion of a human Fc region or a CH3 domain or variants thereof. Table 1 below provides various spacers that can be used in the CARs described herein.

TABLE-US-00001 TABLE 1 Examples of Spacers Name Length Sequence a3 3 aa AAA linker 10 aa GGGSSGGGSG (SEQ ID NO: 14) IgG4 12 aa ESKYGPPCPPCP hinge (SEQ ID NO: 15) (S .fwdarw. P) (S228P) IgG4 12 aa ESKYGPPCPSCP hinge (SEQ ID NO: 52) IgG4 22 aa ESKYGPPCPPCPGGGSSGGGSG hinge + (SEQ ID NO: 16) linker CD28 39 aa IEVMYPPPYLDNEKSNGTIIHVKGKHL hinge CPSPLFPGPSKP (SEQ ID NO: 17) CD8 48 aa AKPTTTPAPRPPTPAPTIASQPLSLRPE hinge- ACRPAAGGAVHTRGLDFACD 48aa (SEQ ID NO: 18) CD8 45 aa TTTPAPRPPTPAPTIASQPLSLRPEACR hinge- PAAGGAVHTRGLDFACD 45aa (SEQ ID NO: 19) IgG4 129 aa ESKYGPPCPPCPGGGSSGGGSGGQPR (HL-CH3) EPQVYTLPPSQEEMTKNQVSLTCLVK GFYPSDIAVEWESNGQPENNYKTTPP VLDSDGSFFLYSRLTVDKSRWQEGNV FSCSVMHEALHNHYTQKSLSLSLGK (SEQ ID NO: 20) IgG4 229 aa ESKYGPPCPSCPAPEFEGGPSVFLFPPK (L235E, PKDTLMISRTPEVTCVVVDVSQEDPE N297Q) VQFNWYVDGVEVHQAKTKPREEQFN STYRVVSVLTVLHQDWLNGKEYKCK VSNKGLPSSIEKTISKAKGQPREPQVY TLPPSQEEMTKNQVSLTCLVKGFYPS DIAVEWESNGQPENNYKTTPPVLDSD GSFFLYSRLTVDKSRWQEGNVFSCSV MHEALHNHYTQKSLSLSLGK (SEQ ID NO: 4) IgG4 229 aa ESKYGPPCPPCPAPEFEGGPSVFLFPPK (S228P, PKDTLMISRTPEVTCVVVDVSQEDPE L235E, VQFNWYVDGVEVHQAKTKPREEQFN N297Q) STYRVVSVLTVLHQDWLNGKEYKCK VSNKGLPSSIEKTISKAKGQPREPQVY TLPPSQEEMTKNQVSLTCLVKGFYPS DIAVEWESNGQPENNYKTTPPVLDSD GSFFLYSRLTVDKSRWQEGNVFSCSV MHEALHNHYTQKSLSLSLGK (SEQ ID NO: 51) IgG4 107 aa GQPREPQVYTLPPSQEEMTKNQVSLT (CH3) CLVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSRLTVDKSRWQ EGNVFSCSVMHEALHNHYTQKSLSLS LGK (SEQ ID NO: 50)

Some spacer regions include all or part of an immunoglobulin (e.g., IgG1, IgG2, IgG3, IgG4) hinge region, i.e., the sequence that falls between the CH1 and CH2 domains of an immunoglobulin, e.g., an IgG4 Fc hinge or a CD8 hinge. Some spacer regions include an immunoglobulin CH3 domain or both a CH3 domain and a CH2 domain. The immunoglobulin derived sequences can include one or more amino acid modifications, for example, 1, 2, 3, 4 or 5 substitutions, e.g., substitutions that reduce off-target binding.

[0017] An "amino acid modification" refers to an amino acid substitution, insertion, and/or deletion in a protein or peptide sequence. An "amino acid substitution" or "substitution" refers to replacement of an amino acid at a particular position in a parent peptide or protein sequence with another amino acid. A substitution can be made to change an amino acid in the resulting protein in a non-conservative manner (i.e., by changing the codon from an amino acid belonging to a grouping of amino acids having a particular size or characteristic to an amino acid belonging to another grouping) or in a conservative manner (i.e., by changing the codon from an amino acid belonging to a grouping of amino acids having a particular size or characteristic to an amino acid belonging to the same grouping). Such a conservative change generally leads to less change in the structure and function of the resulting protein. The following are examples of various groupings of amino acids: 1) Amino acids with nonpolar R groups: Alanine, Valine, Leucine, Isoleucine, Proline, Phenylalanine, Tryptophan, Methionine; 2) Amino acids with uncharged polar R groups: Glycine, Serine, Threonine, Cysteine, Tyrosine, Asparagine, Glutamine; 3) Amino acids with charged polar R groups (negatively charged at pH 6.0): Aspartic acid, Glutamic acid; 4) Basic amino acids (positively charged at pH 6.0): Lysine, Arginine, Histidine (at pH 6.0). Another grouping may be those amino acids with phenyl groups: Phenylalanine, Tryptophan, and Tyrosine.

[0018] In certain embodiments, the spacer is derived from an IgG1, IgG2, IgG3, or IgG4 that includes one or more amino acid residues substituted with an amino acid residue different from that present in an unmodified spacer. The one or more substituted amino acid residues are selected from, but not limited to one or more amino acid residues at positions 220, 226, 228, 229, 230, 233, 234, 235, 234, 237, 238, 239, 243, 247, 267, 268, 280, 290, 292, 297, 298, 299, 300, 305, 309, 218, 326, 330, 331, 332, 333, 334, 336, 339, or a combination thereof. In this numbering scheme, described in greater detail below, the first amino acid in the IgG4(L235E,N297Q) spacer in Table 1 is 219 and the first amino acid in the IgG4(HL-CH3) spacer in Table 1 is 219 as is the first amino acid in the IgG hinge sequence and the IgG4 hinge linker (HL) sequence in Table 1

[0019] In some embodiments, the modified spacer is derived from an IgG1, IgG2, IgG3, or IgG4 that includes, but is not limited to, one or more of the following amino acid residue substitutions: C220S, C226S, S228P, C229S, P230S, E233P, V234A, L234V, L234F, L234A, L235A, L235E, G236A, G237A, P238S, S239D, F243L, P2471, S267E, H268Q, S280H, K290S, K290E, K290N, R292P, N297A, N297Q, S298A, S298G, S298D, S298V, T299A, Y300L, V305I, V309L, E318A, K326A, K326W, K326E, L328F, A330L, A330S, A331S, P331S, 1332E, E333A, E333S, E333S, K334A, A339D, A339Q, P396L, or a combination thereof.

[0020] In certain embodiments, the modified spacer is derived from IgG4 region that includes one or more amino acid residues substituted with an amino acid residue different from that present in an unmodified region. The one or more substituted amino acid residues are selected from, but not limited to, one or more amino acid residues at positions 220, 226, 228, 229, 230, 233, 234, 235, 234, 237, 238, 239, 243, 247, 267, 268, 280, 290, 292, 297, 298, 299, 300, 305, 309, 218, 326, 330, 331, 332, 333, 334, 336, 339, or a combination thereof.

[0021] In some embodiments, the modified spacer is derived from an IgG4 region that includes, but is not limited to, one or more of the following amino acid residue substitutions: 220S, 226S, 228P, 229S, 230S, 233P, 234A, 234V, 234F, 234A, 235A, 235E, 236A, 237A, 238S, 239D, 243L, 2471, 267E, 268Q, 280H, 290S, 290E, 290N, 292P, 297A, 297Q, 298A, 298G, 298D, 298V, 299A, 300L, 305I, 309L, 318A, 326A, 326W, 326E, 328F, 330L, 330S, 331S, 331S, 332E, 333A, 333S, 333S, 334A, 339D, 339Q, 396L, or a combination thereof, wherein the amino acid in the unmodified spacer is substituted with the above identified amino acids at the indicated position.

[0022] For amino acid positions in immunoglobulin discussed herein, numbering is according to the EU index or EU numbering scheme (Kabat et al. 1991 Sequences of Proteins of Immunological Interest, 5th Ed., United States Public Health Service, National Institutes of Health, Bethesda, hereby entirely incorporated by reference). The EU index or EU index as in Kabat or EU numbering scheme refers to the numbering of the EU antibody (Edelman et al. 1969 Proc Natl Acad Sci USA 63:78-85).

[0023] A variety of transmembrane domains can be used in CAR directed against IL13R.alpha.2. Table 2 includes examples of suitable transmembrane domains. Where a spacer domain is present, the transmembrane domain is located carboxy terminal to the spacer domain.

TABLE-US-00002 TABLE 2 Examples of Transmembrane Domains Name Accession Length Sequence CD3z J04132.1 21 aa LCYLLDGILFIYGVI LTALFL (SEQ ID NO: 21) CD28 NM_006139 27 aa FWVLVVVGGVLACYS LLVTVAFIIFWV (SEQ ID NO: 22) CD28 NM_006139 28 aa MFWVLVVVGGVLACY (M) SLLVTVAFIIFWV (SEQ ID NO: 22) CD4 M35160 22 aa MALIVLGGVAGLLLF IGLGIFF (SEQ ID NO: 5) CD8tm NM_001768 21 aa IYIWAPLAGTCGVLL LSLVIT (SEQ ID NO: 23) CD8tm2 NM_001768 23 aa IYIWAPLAGTCGVLL LSLVITLY (SEQ ID NO: 24) CD8tm3 NM_001768 24 aa IYIWAPLAGTCGVLL LSLVITLYC (SEQ ID NO: 25) 41BB NM_001561 27 aa IISFFLALTSTALLF LLFF LTLRFSVV (SEQ ID NO: 26)

[0024] Many of the CAR described herein include one or more (e.g., two) costimulatory domains. The costimulatory domain(s) are located between the transmembrane domain and the CD3.zeta. signaling domain. Table 3 includes examples of suitable costimulatory domains together with the sequence of the CD3.zeta. signaling domain.

TABLE-US-00003 TABLE 3 Examples of Costimulatory Domains Name Accession Length Sequence CD3.zeta. J04132.1 113 aa RVKFSRSADAPAYQQGQNQLYNE LNLGRREEYDVLDKRRGRDPEMG GKPRRKNPQEGLYNELQKDKMAE AYSEIGMKGERRRGKGHDGLYQG LSTATKDTYDALHMQALPPR CD28 NM_006139 42 aa RSKRSRLLHSDYMNMTPRRPGPT RKHYQPYAPPRDFAAYRS (SEQ ID NO: 27) CD28gg* NM_006139 42 aa RSKRSRGGHSDYMNMTPRRPGPT RKHYQPYAPPRDFAAYRS (SEQ ID NO: 28) 41BB NM_001561 42 aa KRGRKKLLYIFKQPFMRPVQTTQ EEDGCSCRFPEEEEGGCEL (SEQ ID NO: 29) OX40 42 aa ALYLLRRDQRLPPDAHKPPGGGS FRTPIQEEQADAHSTLAKI (SEQ ID NO: 30)

DESCRIPTION OF DRAWINGS

[0025] FIG. 1 is a schematic depiction of IL13(E13Y)-zetakine CAR (Left) composed of the IL13R.alpha.2-specific human IL-13 variant (huIL-13(E13Y)), human IgG4 Fc spacer (hu.gamma..sub.4F.sub.c), human CD4 transmembrane (huCD4 tm), and human CD3.zeta. chain cytoplasmic (huCD3.zeta. cyt) portions as indicated. Also depicted is a IL13(EQ)BB.zeta. CAR which is the same as the IL13(E13Y)-zetakine with the exception of the two point mutations, L235E and N297Q indicated in red, that are located in the CH2 domain of the IgG4 spacer, and the addition of a costimulatory 4-1BB cytoplasmic domain (4-1BB cyt).

[0026] FIGS. 2A-C depict certain vectors an open reading frames. A is a diagram of the cDNA open reading frame of the 2670 nucleotide IL13(EQ)BBZ-T2ACD19t construct, where the IL13R.alpha.2-specific ligand IL13(E13Y), IgG4(EQ) Fc hinge, CD4 transmembrane, 4-1BB cytoplasmic signaling, three-glycine linker, and CD3.zeta. cytoplasmic signaling domains of the IL13(EQ)BBZ CAR, as well as the T2A ribosome skip and truncated CD19 sequences are indicated. The human GM-CSF receptor alpha and CD19 signal sequences that drive surface expression of the IL13(EQ)BB.zeta. CAR and CD19t are also indicated. B is a diagram of the sequences flanked by long terminal repeats (indicated by `R`) that will integrate into the host genome. C is a map of the IL13(EQ)BBZ-T2A-CD19t_epHIV7 plasmid.

[0027] FIG. 3 depicts the construction of pHIV7.

[0028] FIG. 4 depicts the elements of pHIV7.

[0029] FIG. 5 depicts a production scheme for IL13(EQ)BB.zeta./CD19t+T.sub.CM.

[0030] FIGS. 6A-C depicts the results of flow cytometric analysis of surface transgene and T cell marker expression. IL13(EQ)BB.zeta./CD19t+T.sub.CM HD006.5 and HD187.1 were co-stained with anti-IL13-PE and anti-CD8-FITC to detect CD8+ CAR+ and CD4+(i.e., CD8 negative) CAR+ cells (A), or anti-CD19-PE and anti-CD4-FITC to detect CD4+CD19t+ and CD8+(i.e., CD4 negative) CAR+ cells (B). IL13(EQ)BB.zeta./CD19t+T.sub.CM HD006.5 and HD187.1 stained with fluorochromeconjugatedanti-CD3, TCR, CD4, CD8, CD62L and CD28 (grey histograms) or isotype controls (black histograms) (C). In all cases the percentages based on viable lymphocytes (DAPI negative) stained above isotype.

[0031] FIGS. 7A-B depict the in vitro functional characterization of IL13R.alpha.2-specific effector function of IL13(EQ)BBZ+ T.sub.CM. IL13(EQ)BBZ/CD19t+T.sub.CMHD006.5 and HD187.1 were used as effectors in a 6-hour .sup.51Cr release assay using a 10:1 E:T ratio based on CD19t expression. The IL13R.alpha.2-positive tumor targets were K562 engineered to express IL13R.alpha.2 (K562-IL13R.alpha.2) and primary glioma line PBT030-2, and the IL13R.alpha.2-negative tumor target control was K562 parental line (A). IL13(EQ)BBZ/CD19t+T.sub.CM HD006.5 and HD187.1 were evaluated for antigen-dependent cytokine production following overnight co-culture at a 10:1 E:T ratio with IL13R.alpha.2-positive and negative targets. Cytokine levels were measured using the Bio-Plex Pro Human Cytokine TH1/TH2 Assay kit and INF-.gamma. are reported (B).

[0032] FIGS. 8A-C depict the result of studies demonstrating the regression of established glioma tumor xenografts after adoptive transfer of IL13(EQ)BB.zeta./CD19t+T.sub.CM. EGFP-ffLuc+ PBT030-2 tumor cells (1.times.10.sup.5) were stereotactically implanted into the right forebrain of NSG mice. On day 5, mice received either 2.times.10.sup.6 IL13(EQ)BB.zeta./CD19t+T.sub.CM (1.1.times.10.sup.6 CAR+; n=6), 2.times.10.sup.6 mock TCM (no CAR; n=6) or PBS (n=6). Representative mice from each group showing relative tumor burden using Xenogen Living Image (A). Quantification of ffLuc flux (photons/sec) shows that IL13(EQ)BB.zeta./CD19t+T.sub.CM induce tumor regression as compared to mock-transduced T.sub.CM and PBS (# p<0.02, *p<0.001, repeated measures ANOVA) (B). Kaplan Meier survival curve (n=6 per group) demonstrating significantly improved survival (p=0.0008; log-rank test) for mice treated with IL13(EQ)BB.zeta./CD19t+T.sub.CM (C)

[0033] FIGS. 9A-C depict the results of studies comparing ant-tumor efficacy of IL13(EQ)BBZ T.sub.CM and IL13-zetakine CTL clones. EGFP-ffLuc+ PBT030-2 TSs (1.times.10.sup.5) were stereotactically implanted into the right forebrain of NSG mice. On day 8, mice received either 1.6.times.10.sup.6 mock T.sub.CM (no CAR), 1.0.times.10.sup.6 CAR+IL13(EQ)BB.zeta. T.sub.CM (1.6.times.10.sup.6 total T cells; 63% CAR), 1.0.times.10.sup.6 IL13-zetakine CD8+ CTL cl. 2D7 (clonal CAR+), or no treatment (n=6 per group). Representative mice from each group showing relative tumor burden using Xenogen Living Image (A). Linear regression lines of natural log of ffLuc flux (photons/sec) over time, P-values are for group by time interaction comparisons (B). Kaplan Meier survival analysis (n=6 per group) demonstrate significantly improved survival (p=0.02; log-rank test) for mice treated with IL13(EQ)BB.zeta. T.sub.CM as compared to IL13-zetakine CD8+ CTL cl. 2D7 (C).

[0034] FIGS. 10A-C depict the results of studies comparing ant-tumor efficacy of IL13(EQ)BB.zeta. T.sub.CM and IL13-zetakine CTL clones. EGFP-ffLuc+ PBT030-2 TSs (1.times.10.sup.5) were stereotactically implanted into the right forebrain of NSG mice. On day 8, mice received either 1.3.times.10.sup.6 mock T.sub.CM (no CAR; n=6), 1.0, 0.3 or 0.1.times.10.sup.6 CAR+IL13(EQ)BB.zeta. T.sub.CM (78% CAR+; n=6-7), 1.0, 0.3 or 0.1.times.10.sup.6 IL13-zetakine CD8+ CTL cl. 2D7 (clonal CAR+; n=6-7), or no treatment (n=5). Xenogen imaging of representative mice from each group showing relative tumor burden (A). Linear regression lines of natural log of ffLuc flux (photons/sec) shows that IL13(EQ)BB.zeta. T.sub.CM achieve superior tumor regression as compared to first-generation IL13-zetakine CTL cl. 2D7, mock T.sub.CM and tumor only (B). Average flux per group at day 27 post tumor injection demonstrating that the 0.1.times.10.sup.6 IL13(EQ)BB.zeta. T.sub.CM dose outperforms the ten-fold higher 1.0.times.10.sup.6 dose of IL13-zetakine CD8+ CTL cl. 2D7 (p=0.043; Welch two sample t-test) (C).

[0035] FIG. 11 depicts the results of studies demonstrating IL13(EQ)BB.zeta. Tcm display improved persistence compared IL13-zetakine CTL clones. CD3 immunohistochemistry evaluating T cell persistence at the tumor site 7-days post T cell infusion. Significant numbers of T cells are detected for IL13(EQ)BB.zeta. Tcm (top panel). By contrast, very few viable CD3+IL13-zetakine T cells are detected (bottom panel).

[0036] FIGS. 12A-D depict the results of experiments comparing route of CAR+ T cell delivery (i.c. versus i.v.) for large established tumors. EGFP-ffLuc+ PBT030-2 TSs (1.times.10.sup.5) were implanted into the right forebrain of NSG mice. On days 19 and 26, mice were injected i.v. through the tail vein with either 5.times.10.sup.6 CAR+IL13(EQ)BB.zeta.+ Tcm (11.8.times.10.sup.6 total cells; n=4), or mock Tcm (11.8.times.10.sup.6 cells; n=4). Alternatively, on days 19, 22, 26 and 29 mice were injected i.c. with either 1.times.10.sup.6 CAR+IL13(EQ)BB.zeta.+ Tcm (2.4.times.10.sup.6 total cells; n=4), or mock Tcm (2.4.times.10.sup.6 cells; n=5). Average ffLuc flux (photons/sec) over time shows that i.c. delivered IL13(EQ)BB.zeta. Tcm mediates tumor regression of day 19 tumors. By comparison, i.v. delivered T cells do not shown reduction in tumor burden as compared to untreated or mock Tcm controls (A). Kaplan Meier survival curve demonstrates improved survival for mice treated i.c. IL13(EQ)BBZ Tcm as compared to mice treated with i.v. administered CAR+ Tcm (p=0.0003 log rank test) (B). Representative H&E and CD3 IHC of mice treated i.v. (C) versus i.c. (D) with IL13(EQ)BBZ+ Tcm. CD3+ T cells were only detected in the i.c. treated group, with no CD3+ cells detected in the tumor or surrounding brain parenchyma for i.v. treated mice.

[0037] FIGS. 13A-B depict the results of studies showing that CAR+ T cell injected intracranially, either intratumoral (i.c.t.) or intraventricular (i.c.v.), can traffic to tumors on the opposite hemisphere. EGFP-ffLuc+ PBT030-2 TSs (1.times.105) were stereotactically implanted into the right and left forebrains of NSG mice. On day 6, mice were injected i.c. at the right tumor site with 1.0.times.106 IL13(EQ)BB.zeta.+ Tcm (1.6.times.106 total cells; 63% CAR; n=4). Schematic of multifocal glioma experimental model (A). CD3 IHC showing T cells infiltrating both the right and left tumor sites (B).

[0038] FIGS. 14A-C depict the results of a series of studies evaluating costimulatory domains of IL13R.alpha.2-specific CAR. Schematic of IL13R.alpha.2-specific CAR constructs comparing various intracellular endo/signaling domains, including the first generation CD3z CAR lacking costimulation, versus second generation CARs incorporating either 4-1BB or CD28, versus a third generation CAR containing both CD28 and 41BB. All CAR cassettes also contain the T2A ribosomal skip and truncated CD19 (CD19t) sequences as a marker for transduced cells (A). CD4 and CD8 TCM were lentivirally transduced and CAR-expressing T cells were immunomagnetically enriched via anti-CD19. CD19 and IL13 (i.e., CAR) expression levels as measured by flow cytometry (B). Stability of each CAR construct was determined by dividing the CAR (IL13) mean flourescence intensity (MFI) by that of the transduction marker (CD19t) (C). The 4-1BB containing CARs demonstrated the lowest expression levels as compared to the CD19t transduction marker.

[0039] FIGS. 15A-B depict the results of studies demonstrating that IL13R.alpha.2-specific CAR containing the 4-1BB costimulatory domain produce less Th1 and Th2 cytokines. The ability of the indicated mock-transduced or CAR-expressing T cells to kill IL13R.alpha.2-expressing PBT030-2 tumor cell targets was determined in a 4-hour 51Cr-release assay at the indicated effector:target ratios. Mean % chromium release+S.D. of triplicate wells are depicted (A). As expected, mock-transduced T cells did not efficiently lyse the targets. In contrast, all CAR-expressing T cells lysed the tumor cells in a similar manner. The indicated mock-transduced or CAR-expressing T cells were co-cultured overnight with IL13R.alpha.2-expressing PBT030-2 tumor cells at a 10:1 ratio and supernatants were analyzed for IL-13 and IFN-.gamma. levels by cytometric bead array (B). Means+S.D. of triplicate wells are depicted. Interestingly, T cells expressing the zeta, 41BB-zeta or CD28-41BB-zeta CARs exhibited lower antigen-stimulated cytokine production than T cells expressing the CD28-zeta CAR.

[0040] FIGS. 16A-C depict the results of a series of studies of the in vivo efficacy of IL13R.alpha.2-specific CARs. NSG mice received an intracranial injection of ffLuc+ PBT030-2 tumor cells on day 0, and were randomized into 6 groups (n=9-10 mice per group) for i.c. treatment with either PBS (Tumor Only), mock-transduced T cells or T cells expressing the indicated IL13R.alpha.2-specific CAR on day 8. Quantitative bioluminescence imaging was then carried out to monitor tumor growth over time. Bioluminescence images for representative mice in each group (A). Mean+S.E. of total flux levels of luciferase activity over time in each group (B). Flux levels for each mouse at Day 27. All groups treated with IL13R.alpha.2-specific CAR T cells, except those treated with T cells expressing the CD28-CAR, show statistically-significant reduction in tumor volume compared to mice treated with mock-transduced T cells (C)

[0041] FIGS. 17A-B depict the amino acid sequence of IL13(EQ)BB.zeta./CD19t+(SEQ ID NO:10).

[0042] FIGS. 18A-0 depict a sequence comparison of IL13(EQ)41BB.zeta.[IL13{EQ}41BK T2A-CD19t_epHIV7; pF02630] (SEQ ID NO:12) and CD19Rop_epHIV7 (pJ01683) (SEQ ID NO:13).

[0043] FIG. 19 depicts the amino acid sequence of IL13(EmY)-CD8h3-CD8tm2-41BB Zeta (SEQ ID NO:31 with GMSCFRa signal peptide; SEQ ID NO:39 without GMSCFRa signal peptide).

[0044] FIG. 20 depicts the amino acid sequence of IL13(EmY)-CD8h3-CD28tm-CD28gg-41BB-Zeta (SEQ ID NO:32 with GMSCFRa signal peptide; SEQ ID NO:40 without GMSCFRa signal peptide).

[0045] FIG. 21 depicts the amino acid sequence of IL13(EmY)-IgG4(HL-CH3)-CD4tm-41BB-Zeta (SEQ ID NO:33 with GMSCFRa signal peptide; SEQ ID NO:41 without GMSCFRa signal peptide).

[0046] FIG. 22 depicts the amino acid sequence of IL13(EmY)-IgG4(L235E,N297Q)-CD8tm-41BB-Zeta (SEQ ID NO:34 with GMSCFRa signal peptide; SEQ ID NO:42 without GMSCFRa signal peptide).

[0047] FIG. 23 depicts the amino acid sequence of IL13(EmY)-Linker-CD28tm-CD28gg-41BB-Zeta (SEQ ID NO:35 with GMSCFRa signal peptide; SEQ ID NO:43 without GMSCFRa signal peptide).

[0048] FIG. 24 depicts the amino acid sequence of IL13(EmY)-HL-CD28m-CD28gg-41BB-Zeta (SEQ ID NO:36 with GMSCFRa signal peptide; SEQ ID NO:44 without GMSCFRa signal peptide).

[0049] FIG. 25 depicts the amino acid sequence of IL13(EmY)-IgG4(HL-CH3)-CD28tm-CD28gg-41BB-Zeta (SEQ ID NO:37 with GMSCFRa signal peptide; SEQ ID NO:45 without GMSCFRa signal peptide).

[0050] FIG. 26 depicts the amino acid sequence of IL13(EmY) IgG4(L235E,N297Q)-CD28tm-CD28gg-41BB-Zeta (SEQ ID NO:38 with GMSCFRa signal peptide; SEQ ID NO:46 without GMSCFRa signal peptide).

[0051] FIG. 27 depicts the amino acid sequence of IL13(EmY)-CD8h3-CD8tm-41BB Zeta (SEQ ID NO:47 with GMSCFRa signal peptide; SEQ ID NO:48 without GMSCFRa signal peptide).

DETAILED DESCRIPTION

[0052] Described below is the structure, construction and characterization of various IL13R.alpha.2-specific chimeric antigen receptors. A chimeric antigen (CAR) is a recombinant biomolecule that contains, at a minimum, an extracellular recognition domain, a transmembrane region, and an intracellular signaling domain. The term "antigen," therefore, is not limited to molecules that bind antibodies, but to any molecule that can bind specifically to a target. For example, a CAR can include a ligand that specifically binds a cell surface receptor. The extracellular recognition domain (also referred to as the extracellular domain or simply by the recognition element which it contains) comprises a recognition element that specifically binds to a molecule present on the cell surface of a target cell. The transmembrane region anchors the CAR in the membrane. The intracellular signaling domain comprises the signaling domain from the zeta chain of the human CD3 complex and optionally comprises one or more costimulatory signaling domains. CARs can both to bind antigen and transduce T cell activation, independent of MHC restriction. Thus, CARs are "universal" immunoreceptors which can treat a population of patients with antigen-positive tumors irrespective of their HLA genotype. Adoptive immunotherapy using T lymphocytes that express a tumor-specific CAR can be a powerful therapeutic strategy for the treatment of cancer.

[0053] One IL13R.alpha.2-specific CAR described herein is referred to as IL13(EQ)BB.zeta.. This CAR includes a variety of important features including: a IL13.alpha.2 ligand having an amino acid change that improves specificity of biding to IL13.alpha.2; the domain of CD137 (4-1BB) in series with CD3.zeta. to provide beneficial costimulation; and an IgG4 Fc region that is mutated at two sites within the CH2 region (L235E; N297Q) in a manner that reduces binding by Fc receptors (FcRs). Other CAR described herein contain a second costimulatory domain.

[0054] In some cases the CAR described herein, including the IL13(EQ)BB.zeta.CAR can be produced using a vector in which the CAR open reading frame is followed by a T2A ribosome skip sequence and a truncated CD19 (CD19t), which lacks the cytoplasmic signaling tail (truncated at amino acid 323). In this arrangement, co-expression of CD19t provides an inert, non-immunogenic surface marker that allows for accurate measurement of gene modified cells, and enables positive selection of gene-modified cells, as well as efficient cell tracking and/or imaging of the therapeutic T cells in vivo following adoptive transfer. Co-expression of CD19t provides a marker for immunological targeting of the transduced cells in vivo using clinically available antibodies and/or immunotoxin reagents to selectively delete the therapeutic cells, and thereby functioning as a suicide switch.

[0055] Gliomas, express IL13 receptors, and in particular, high-affinity IL13 receptors. However, unlike the IL13 receptor, glioma cells overexpress a unique IL13R.alpha.2 chain capable of binding IL13 independently of the requirement for IL4RP or yc44. Like its homolog IL4, IL13 has pleotropic immunoregulatory activity outside the CNS. Both IL13 and IL4 stimulate IgE production by B lymphocytes and suppress pro-inflammatory cytokine production by macrophages.

[0056] Detailed studies using autoradiography with radiolabeled IL13 have demonstrated abundant IL13 binding on nearly all malignant glioma tissues studied. This binding is highly homogeneous within tumor sections and in single cell analysis. However, molecular probe analysis specific for IL13R.alpha.2 mRNA did not detect expression of the glioma-specific receptor by normal brain elements and autoradiography with radiolabeled IL13 also could not detect specific IL13 binding in the normal CNS. These studies suggest that the shared IL13R.alpha.1/IL4.beta./.gamma.c receptor is not expressed detectably in the normal CNS. Therefore, IL13R.alpha.2 is a very specific cell-surface target for glioma and is a suitable target for a CAR designed for treatment of a glioma.

[0057] Binding of IL13-based therapeutic molecules to the broadly expressed IL13R.alpha.1/IL4.beta./.gamma.c receptor complex, however, has the potential of mediating undesired toxicities to normal tissues outside the CNS, and thus limits the systemic administration of these agents. An amino acid substitution in the IL13 alpha helix A at amino acid 13 of tyrosine for the native glutamic acid selectively reduces the affinity of IL13 to the IL13R.alpha.1/IL4.beta./.gamma.c receptor. Binding of this mutant (termed IL13(E13Y)) to IL13R.alpha.2, however, was increased relative to wild-type IL13. Thus, this minimally altered IL13 analog simultaneously increases IL13's specificity and affinity for glioma cells. Therefore, CAR described herein include an IL13 containing a mutation (E to Y or E to some other amino acid such as K or R or L or V) at amino acid 13 (according to the numbering of Debinski et al. 1999 Clin Cancer Res 5:3143s). IL13 having the natural sequence also may be used, however, and can be useful, particularly in situations where the modified T cells are to be locally administered, such as by injection directly into a tumor mass.

[0058] The CAR described herein can be produced by any means known in the art, though preferably it is produced using recombinant DNA techniques. Nucleic acids encoding the several regions of the chimeric receptor can be prepared and assembled into a complete coding sequence by standard techniques of molecular cloning known in the art (genomic library screening, PCR, primer-assisted ligation, site-directed mutagenesis, etc.) as is convenient. The resulting coding region is preferably inserted into an expression vector and used to transform a suitable expression host cell line, preferably a T lymphocyte cell line, and most preferably an autologous T lymphocyte cell line.

[0059] Various T cell subsets isolated from the patient, including unselected PBMC or enriched CD3 T cells or enriched CD3 or memory T cell subsets, can be transduced with a vector for CAR expression. Central memory T cells are one useful T cell subset. Central memory T cell can be isolated from peripheral blood mononuclear cells (PBMC) by selecting for CD45RO+/CD62L+ cells, using, for example, the CliniMACS.RTM. device to immunomagnetically select cells expressing the desired receptors. The cells enriched for central memory T cells can be activated with anti-CD3/CD28, transduced with, for example, a SIN lentiviral vector that directs the expression of an IL13R.alpha.2-specific CAR (e.g., IL13(EQ)BB.zeta.) as well as a truncated human CD19 (CD19t), a non-immunogenic surface marker for both in vivo detection and potential ex vivo selection. The activated/genetically modified central memory T cells can be expanded in vitro with IL-2/IL-15 and then cryopreserved.

Example 1: Construction and Structure of an IL13R.alpha.2-Specific CAR

[0060] The structure of a useful IL13R.alpha.2-specific CAR is described below. The codon optimized CAR sequence contains a membrane-tethered IL-13 ligand mutated at a single site (E13Y) to reduce potential binding to IL13R.alpha.1, an IgG4 Fc spacer containing two mutations (L235E; N297Q) that greatly reduce Fc receptor-mediated recognition models, a CD4 transmembrane domain, a costimulatory 4-1BB cytoplasmic signaling domain, and a CD3.zeta. cytoplasmic signaling domain. A T2A ribosome skip sequence separates this IL13(EQ)BB.zeta. CAR sequence from CD19t, an inert, non-immunogenic cell surface detection/selection marker. This T2A linkage results in the coordinate expression of both IL13(EQ)BB.zeta. and CD19t from a single transcript. FIG. 2A is a schematic drawing of the 2670 nucleotide open reading frame encoding the IL13(EQ)BBZ-T2ACD19t construct. In this drawing, the IL13R.alpha.2-specific ligand IL13(E13Y), IgG4(EQ) Fc, CD4 transmembrane, 4-1BB cytoplasmic signaling, three-glycine linker, and CD3.zeta. cytoplasmic signaling domains of the IL13(EQ)BBZ CAR, as well as the T2A ribosome skip and truncated CD19 sequences are all indicated. The human GM-CSF receptor alpha and CD19 signal sequences that drive surface expression of the IL13(EQ)BBZ CAR and CD19t are also indicated. Thus, the IL13(EQ)BBZ-T2ACD19t construct includes a IL13R.alpha.2-specific, hinge-optimized, costimulatory chimeric immunoreceptor sequence (designated IL13(EQ)BBZ), a ribosome-skip T2A sequence, and a CD19t sequence.

[0061] The IL13(EQ)BBZ sequence was generated by fusion of the human GM-CSF receptor alpha leader peptide with IL13(E13Y) ligand 5 L235E/N297Q-modified IgG4 Fc hinge (where the double mutation interferes with FcR recognition), CD4 transmembrane, 4-1BB cytoplasmic signaling domain, and CD3.zeta. cytoplasmic signaling domain sequences. This sequence was synthesized de novo after codon optimization. The T2A sequence was obtained from digestion of a T2A-containing plasmid. The CD19t sequence was obtained from that spanning the leader peptide sequence to the transmembrane components (i.e., basepairs 1-972) of a CD19-containing plasmid. All three fragments, 1) IL13(EQ)BBZ, 2) T2A, and 3) CD19t, were cloned into the multiple cloning site of the epHIV7 lentiviral vector. When transfected into appropriate cells, the vector integrates the sequence depicted schematically in FIG. 2B into the host cells genome. FIG. 2C provides a schematic drawing of the 9515 basepair IL13(EQ)BBZ-T2A-CD19t_epHIV7 plasmid itself.

[0062] As shown schematically in FIG. 1, IL13(EQ)BBZ CAR differs in several important respects from a previously described IL13R.alpha.2-specific CAR referred to as IL13(E13Y)-zetakine (Brown et al. 2012 Clinical Cancer Research 18:2199). The IL13(E13Y)-zetakine is composed of the IL13R.alpha.2-specific human IL-13 mutein (huIL-13(E13Y)), human IgG4 Fc spacer (hu.gamma.4Fc), human CD4 transmembrane (huCD4 tm), and human CD3.zeta. chain cytoplasmic (huCD3.zeta. cyt) portions as indicated. In contrast, the IL13(EQ)BB.zeta.) has two point mutations, L235E and N297Q that are located in the CH2 domain of the IgG4 spacer, and a costimulatory 4-1BB cytoplasmic domain (4-1BB cyt).

Example 2: Construction and Structure of epHIV7 Used for Expression of an IL13R.alpha.2-Specific CAR

[0063] The pHIV7 plasmid is the parent plasmid from which the clinical vector IL13(EQ)BBZ-T2A-CD19t_epHIV7 was derived in the T cell Therapeutics Research Laboratory (TCTRL) at City of Hope (COH). The epHIV7 vector used for expression of the CAR was produced from pHIV7 vector. Importantly, this vector uses the human EF1 promoter to drive expression of the CAR. Both the 5' and 3' sequences of the vector were derived from pv653RSN as previously derived from the HXBc2 provirus. The polypurine tract DNA flap sequences (cPPT) were derived from HIV-1 strain pNL4-3 from the NIH AIDS Reagent Repository. The woodchuck post-transcriptional regulatory element (WPRE) sequence was previously described.

[0064] Construction of pHIV7 is schematically depicted in FIG. 3. Briefly, pv653RSN, containing 653 bp from gag-pol plus 5' and 3' long-terminal repeats (LTRs) with an intervening SL3-neomycin phosphotransferase gene (Neo), was subcloned into pBluescript, as follows: In Step 1, the sequences from 5' LTR to rev-responsive element (RRE) made p5'HIV-1 51, and then the 5' LTR was modified by removing sequences upstream of the TATA box, and ligated first to a CMV enhancer and then to the SV40 origin of replication (p5'HIV-2). In Step 2, after cloning the 3' LTR into pBluescript to make p3'HIV-1, a 400-bp deletion in the 3' LTR enhancer/promoter was made to remove cis-regulatory elements in HIV U3 and form p3'HIV-2. In Step 3, fragments isolated from the p5'HIV-3 and p3'HIV-2 were ligated to make pHIV-3. In Step 4, the p3'HIV-2 was further modified by removing extra upstream HIV sequences to generate p3'HIV-3 and a 600-bp BamHI-SalI fragment containing WPRE was added to p3'HIV-3 to make the p3'HIV-4. In Step 5, the pHIV-3 RRE was reduced in size by PCR and ligated to a 5' fragment from pHIV-3 (not shown) and to the p3'HIV-4, to make pHIV-6. In Step 6, a 190-bp BglII-BamHI fragment containing the cPPT DNA flap sequence from HIV-1 pNL4-3 (55) was amplified from pNL4-3 and placed between the RRE and the WPRE sequences in pHIV6 to make pHIV-7. This parent plasmid pHIV7-GFP (GFP, green fluorescent protein) was used to package the parent vector using a four-plasmid system.

[0065] A packaging signal, psi w, is required for efficient packaging of viral genome into the vector. The RRE and WPRE enhance the RNA transcript transport and expression of the transgene. The flap sequence, in combination with WPRE, has been demonstrated to enhance the transduction efficiency of lentiviral vector in mammalian cells.

[0066] The helper functions, required for production of the viral vector), are divided into three separate plasmids to reduce the probability of generation of replication competent lentivirus via recombination: 1) pCgp encodes the gag/pol protein required for viral vector assembly; 2) pCMV-Rev2 encodes the Rev protein, which acts on the RRE sequence to assist in the transportation of the viral genome for efficient packaging; and 3) pCMV-G encodes the glycoprotein of the vesiculo-stomatitis virus (VSV), which is required for infectivity of the viral vector.

[0067] There is minimal DNA sequence homology between the pHIV7 encoded vector genome and the helper plasmids. The regions of homology include a packaging signal region of approximately 600 nucleotides, located in the gag/pol sequence of the pCgp helper plasmid; a CMV promoter sequence in all three helper plasmids; and a RRE sequence in the helper plasmid pCgp. It is highly improbable that replication competent recombinant virus could be generated due to the homology in these regions, as it would require multiple recombination events. Additionally, any resulting recombinants would be missing the functional LTR and tat sequences required for lentiviral replication.

[0068] The CMV promoter was replaced by the EF1.alpha.-HTLV promoter (EF1p), and the new plasmid was named epHIV7 (FIG. 4). The EF1p has 563 bp and was introduced into epHIV7 using NruI and NheI, after the CMV promoter was excised.

[0069] The lentiviral genome, excluding gag/pol and rev that are necessary for the pathogenicity of the wild-type virus and are required for productive infection of target cells, has been removed from this system. In addition, the IL13(EQ)BBZ-T2ACD19t_epHIV7 vector construct does not contain an intact 3'LTR promoter, so the resulting expressed and reverse transcribed DNA proviral genome in targeted cells will have inactive LTRs. As a result of this design, no HIV-I derived sequences will be transcribed from the provirus and only the therapeutic sequences will be expressed from their respective promoters. The removal of the LTR promoter activity in the SIN vector is expected to significantly reduce the possibility of unintentional activation of host genes (56). Table 4 summarizes the various regulator elements present in IL13(EQ)BBZ-T2ACD19t_epHIV7.

TABLE-US-00004 TABLE 4 Functional elements of IL13(EQ)41BBZ-T2A-CD19t_epHIV7 Location Regulatory Elements (Nucleotide and Genes Numbers) Comments U5 87-171 5' Unique sequence psi 233-345 Packaging signal RRE 957-1289 Rev-responsive element flap 1290-1466 Contains polypurine track sequence and central termination sequence to facilitate nuclear import of pre-integration complex EF1p Promoter 1524-2067 EF1-alpha Eukaryotic Promoter sequence driving expression of CD19Rop IL13-IgG4 (EQ)- 2084-4753 Therapeutic insert 41BB-Zeta-T2A- CD19t WPRE 4790-5390 Woodchuck hepatitis virus derived regulatory element to enhance viral RNA transportation delU3 5405-5509 3' U3 with deletion to generate SIN vector R 5510-5590 Repeat sequence within LTR U5 5591-5704 3' U5 sequence in LTR Amp.sup.R 6540-7398 Ampicillin-resistance gene CoE1 ori 7461-8342 Replication origin of plasmid SV40 ori 8639-8838 Replication origin of SV40 CMV promoter 8852-9451 CMV promoter to generate viral genome RNA R 9507-86 Repeat sequence within LTR

Example 3: Production of Vectors for Transduction of Patient T Cells

[0070] For each plasmid (IL13(EQ)BBZ-T2A-CD19t_epHIV7; pCgp; pCMV-G; and pCMV-Rev2), a seed bank is generated, which is used to inoculate the fermenter to produce sufficient quantities of plasmid DNA. The plasmid DNA is tested for identity, sterility and endotoxin prior to its use in producing lentiviral vector.

[0071] Briefly, cells were expanded from the 293T working cell (WCB), which has been tested to confirm sterility and the absence of viral contamination. A vial of 293T cells from the 293T WCB was thawed. Cells were grown and expanded until sufficient numbers of cells existed to plate an appropriate number of 10 layer cell factories (CFs) for vector production and cell train maintenance. A single train of cells can be used for production.

[0072] The lentiviral vector was produced in sub-batches of up to 10 CFs. Two sub-batches can be produced in the same week leading to the production of approximately 20 L of lentiviral supernatant/week. The material produced from all sub-batches were pooled during the downstream processing phase, in order to produce one lot of product. 293T cells were plated in CFs in 293T medium (DMEM with 10% FBS). Factories were placed in a 37.degree. C. incubator and horizontally leveled in order to get an even distribution of the cells on all the layers of the CF. Two days later, cells were transfected with the four lentiviral plasmids described above using the CaPO4 method, which involves a mixture of Tris:EDTA, 2M CaCl2, 2.times.HBS, and the four DNA plasmids. Day 3 after transfection, the supernatant containing secreted lentiviral vectors was collected, purified and concentrated. After the supernatant was removed from the CFs, End-of-Production Cells were collected from each CF. Cells were trypsinized from each factory and collected by centrifugation. Cells were resuspended in freezing medium and cryopreserved. These cells were later used for replication-competent lentivirus (RCL) testing.

[0073] To purify and formulate vectors crude supernatant was clarified by membrane filtration to remove the cell debris. The host cell DNA and residual plasmid DNA were degraded by endonuclease digestion (Benzonase.RTM.). The viral supernatant was clarified of cellular debris using a 0.45 .mu.m filter. The clarified supernatant was collected into a pre-weighed container into which the Benzonase.RTM. is added (final concentration 50 U/mL). The endonuclease digestion for residual plasmid DNA and host genomic DNA as performed at 37.degree. C. for 6 h. The initial tangential flow ultrafiltration (TFF) concentration of the endonuclease-treated supernatant was used to remove residual low molecular weight components from the crude supernatant, while concentrating the virus .about.20 fold. The clarified endonuclease-treated viral supernatant was circulated through a hollow fiber cartridge with a NMWCO of 500 kD at a flow rate designed to maintain the shear rate at .about.4,000 sec-1 or less, while maximizing the flux rate. Diafiltration of the nuclease-treated supernatant was initiated during the concentration process to sustain the cartridge performance. An 80% permeate replacement rate was established, using 4% lactose in PBS as the diafiltration buffer. The viral supernatant was brought to the target volume, representing a 20-fold concentration of the crude supernatant, and the diafiltration was continued for 4 additional exchange volumes, with the permeate replacement rate at 100%.

[0074] Further concentration of the viral product was accomplished by using a high speed centrifugation technique. Each sub-batch of the lentivirus was pelleted using a Sorvall RC-26 plus centrifuge at 6000 RPM (6,088 RCF) at 6.degree. C. for 16-20 h. The viral pellet from each sub-batch was then reconstituted in a 50 mL volume with 4% lactose in PBS. The reconstituted pellet in this buffer represents the final formulation for the virus preparation. The entire vector concentration process resulted in a 200-fold volume reduction, approximately. Following the completion of all of the sub-batches, the material was then placed at -80.degree. C., while samples from each sub-batch were tested for sterility. Following confirmation of sample sterility, the sub-batches were rapidly thawed at 37.degree. C. with frequent agitation. The material was then pooled and manually aliquoted in the Class II Type A/B3 biosafety cabinet in the viral vector suite. A fill configuration of 1 mL of the concentrated lentivirus in sterile USP class 6, externally threaded O-ring cryovials was used. Center for Applied Technology Development (CATD)'s Quality Systems (QS) at COH released all materials according to the Policies and Standard Operating Procedures for the CBG and in compliance with current Good Manufacturing Practices (cGMPs).

[0075] To ensure the purity of the lentiviral vector preparation, it was tested for residual host DNA contaminants, and the transfer of residual host and plasmid DNA. Among other tests, vector identity was evaluated by RT-PCR to ensure that the correct vector is present. All release criteria were met for the vector intended for use in this study.

Example 4: Preparation of T Cells Suitable for Use in ACT

[0076] T lymphocytes are obtained from a patient by leukopheresis, and the appropriate allogenic or autologous T cell subset, for example, Central Memory T cells (T.sub.CM), are genetically altered to express the CAR, then administered back to the patient by any clinically acceptable means, to achieve anti-cancer therapy.

[0077] An outline of the manufacturing strategy for T.sub.CM is depicted in FIG. 8 (Manufacturing schema for IL13(EQ)BB.zeta./CD19t+T.sub.CM). Specifically, apheresis products obtained from consented research participants are ficolled, washed and incubated overnight. Cells are then depleted of monocyte, regulatory T cell and naive T cell populations using GMP grade anti-CD14, anti-CD25 and anti-CD45RA reagents (Miltenyi Biotec) and the CliniMACS.TM. separation device. Following depletion, negative fraction cells are enriched for CD62L+T.sub.CM cells using DREG56-biotin (COH clinical grade) and anti-biotin microbeads (Miltenyi Biotec) on the CliniMACS.TM. separation device.

[0078] Following enrichment, T.sub.CM cells are formulated in complete X-Vivo15 plus 50 IU/mL IL-2 and 0.5 ng/mL IL-15 and transferred to a Teflon cell culture bag, where they are stimulated with Dynal ClinEx.TM. Vivo CD3/CD28 beads. Up to five days after stimulation, cells are transduced with IL13(EQ)BBZ-T2A-CD19t_epHIV7 lentiviral vector at a multiplicity of infection (MOI) of 1.0 to 0.3. Cultures are maintained for up to 42 days with addition of complete X-Vivo15 and IL-2 and IL-15 cytokine as required for cell expansion (keeping cell density between 3.times.10.sup.5 and 2.times.10.sup.6 viable cells/mL, and cytokine supplementation every Monday, Wednesday and Friday of culture). Cells typically expand to approximately 10.sup.9 cells under these conditions within 21 days. At the end of the culture period cells are harvested, washed twice and formulated in clinical grade cryopreservation medium (Cryostore CS5, BioLife Solutions).

[0079] On the day(s) of T cell infusion, the cryopreserved and released product is thawed, washed and formulated for re-infusion. The cryopreserved vials containing the released cell product are removed from liquid nitrogen storage, thawed, cooled and washed with a PBS/2% human serum albumin (HSA) Wash Buffer. After centrifugation, the supernatant is removed and the cells resuspended in a Preservative-Free Normal Saline (PFNS)/2% HSA infusion diluent. Samples are removed for quality control testing.

[0080] Two qualification runs on cells procured from healthy donors were performed using the manufacturing platform described above. Each preclinical qualification run product was assigned a human donor (HD) number--HD006.5 and HD187.1. Importantly, as shown in Table 5, these qualification runs expanded >80 fold within 28 days and the expanded cells expressed the IL13(EQ)BB.gamma./CD19t transgenes.

TABLE-US-00005 TABLE 5 Summary of Expression Data from Pre-clinical Qualification Run Product Cell Product CAR CD19 CD4+ CD8+ Fold Expansion HD006.5 20% 22% 24% 76% 84-fold (28 days) Hd187.1 18% 25% 37% 63% 259-fold (28 days)

Example 5: Flow Cytometric Analysis of Surface Transgene and T Cell Marker Expression in IL13(EQ)BB.gamma./CD19t+T.sub.CM

[0081] The two preclinical qualification run products described in Example 4 were used in pre-clinical studies to as described below. FIGS. 6A-C depict the results of flow cytometric analysis of surface transgene and T cell marker expression. IL13(EQ)BB.gamma./CD19t+T.sub.CM HD006.5 and HD187.1 were co-stained with anti-IL13-PE and anti-CD8-FITC to detect CD8+ CAR+ and CD4+(i.e., CD8 negative) CAR+ cells (FIG. 6A), or anti-CD19-PE and anti-CD4-FITC to detect CD4+CD19t+ and CD8+(i.e., CD4 negative) CAR+ cells (FIG. 6B). IL13(EQ)BB.gamma./CD19t+T.sub.CM HD006.5 and HD187.1 were stained with fluorochrome-conjugated anti-CD3, TCR, CD4, CD8, CD62L and CD28 (grey histograms) or isotype controls (black histograms). (FIG. 6C). In each of FIGS. 6A-C, the percentages indicated are based on viable lymphocytes (DAPI negative) stained above isotype.

Example 6: Effector Activity of IL13(EQ)BB.gamma./CD19t+T.sub.CM

[0082] The effector activity of IL13(EQ)BB.zeta./CD19t+T.sub.CM was assessed and the results of this analysis are depicted in FIGS. 7A-B. Briefly, IL13(EQ)BB.gamma./CD19t+T.sub.CM HD006.5 and HD187.1 were used as effectors in a 6-hour 51Cr-release assay using a 10E:1T ratio based on CD19t expression. The IL13R.alpha.2-positive tumor targets were K562 engineered to express IL13R.alpha.2 (K562-IL13R.alpha.2) and primary glioma line PBT030-2, and the IL13R.alpha.2-negative tumor target control was the K562 parental line (FIG. 7A). IL13(EQ)BB.gamma./CD19t+HD006.5 and HD187.1 were evaluated for antigen-dependent cytokine production following overnight co-culture at a 10E:1T ratio with the same IL13R.alpha.2-positive and negative targets as described in above. Cytokine levels were measured using the Bio-Plex Pro Human Cytokine TH1/TH2 Assay kit and INF-.gamma. levels are depicted (FIG. 7B).

Example 7: In Vivo Anti-Tumor Activity of IL13(EQ)BB.gamma./CD19t+T.sub.CM

[0083] The studies described below demonstrate that IL13(EQ)BB.gamma./CD19t+T.sub.CM exhibit anti-tumor efficacy in in vivo mouse models. Specifically, we have evaluated the anti-tumor potency of IL13(EQ)BB.gamma./CD19t+T.sub.CM against the IL13R.alpha.2+ primary low-passage glioblastoma tumor sphere line PBT030-2, which has been engineered to express both EGFP and firefly luciferase (ffLuc) reporter genes (PBT030-2 EGFP:ffLuc) (6). A panel of primary lines (PBT) from patient glioblastoma specimens grown as tumor spheres (TSs) in serum-free media. These expanded TS lines exhibit stem cell-like characteristics, including expression of stem cell markers, multilineage differentiation and capacity to initiate orthotopic tumors in immunocompromised mice (NSG) at low cell numbers. The PBT030-2 EGFP:ffLuc TS-initiated xenograft model (0.1.times.10.sup.6 cells; 5 day engraftment) has been previously used to evaluate in vivo anti-tumor activity in NSG mice of IL13R.alpha.2-specific CAR expressing T cells, whereby three injections of 2.times.10.sup.6 cytolytic T lymphocytes (CTLs) over a course of 2 weeks were shown to reduce tumor growth. However, in those experiments the majority of the PBT030-2 tumors eventually recurred. By comparison, a single injection of IL13(EQ)BB.gamma./CD19t+T.sub.CM (1.1.times.10.sup.6 CAR+T.sub.CM; 2.times.10.sup.6 total TCM) exhibited robust anti-tumor activity against PBT030-2 EGFP:ffLuc TS-initiated tumors (0.1.times.10.sup.6 cells; 5 day engraftment) as shown in FIGS. 8A-C. As compared to NSG mice treated with either PBS or mock transduced T.sub.CM (no CAR), IL13(EQ)BB.gamma./CD19t+T.sub.CM significantly reduce ffLuc flux (p<0.001 at >18-days) and significantly improve survival (p=0.0008).

[0084] Briefly, EGFP-ffLuc+ PBT030-2 tumor cells (1.times.10.sup.5) were stereotactically implanted into the right forebrain of NSG mice. On day 5, mice received either 2.times.10.sup.6 IL13(EQ)BB.gamma./CD19t+T.sub.CM (1.1.times.106 CAR+; n=6), 2.times.10.sup.6 mock T.sub.CM (no CAR; n=6) or PBS (n=6). FIG. 8A depicts representative mice from each group showing relative tumor burden using Xenogen Living Image. Quantification of ffLuc flux (photons/sec) shows that IL13(EQ)BB.zeta./CD19t+T.sub.CM induce tumor regression as compared to mock-transduced T.sub.CM and PBS (# p<0.02, *p<0.001, repeated measures ANOVA) (FIG. 8B). As shown in FIG. 8C, a Kaplan Meier survival curve (n=6 per group) demonstrates significantly improved survival (p=0.0008; log-rank test) for mice treated with IL13(EQ)BB.gamma./CD19t+T.sub.CM.

Example 8: Comparison of IL13(EQ)BB.zeta.+Tcm and Non-Tcm IL13-Zetakine CD8+ CTL Clones in Antitumor Efficacy and T Cell Persistence

[0085] The studies described below compare IL13(EQ)BB.zeta.+Tcm and a previously created IL13R.alpha.2-specific human CD8+ CTLs (IL13-zetakine CD8+ CTL (described in Brown et al. 2012 Clin Cancer Res 18:2199 and Kahlon et al. 2004 Cancer Res 64:9160). The IL13-zetakine uses a CD3 stimulatory domain, lacks a co-stimulatory domain and uses the same IL13 variant as IL13(EQ)BB.zeta.+.

[0086] A panel of primary lines (PBT) from patient glioblastoma specimens grown as tumor spheres (TSs) in serum-free media was generated (Brown et al. 2012 Clin Cancer Res 18:2199; Brown et al. 2009 Cancer Res 69:8886). These expanded TS lines exhibit stem cell-like characteristics, including expression of stem cell markers, multi-lineage differentiation and capacity to initiate orthotopic tumors in immunocompromised mice (NSG) at low cell numbers. The IL13R.alpha.2+ primary low-passage glioblastoma TS line PBT030-2, which has been engineered to express both EGFP and firefly luciferase (ffLuc) reporter genes (PBT030-2 EGFP:ffLuc) (Brown et al. 2012 Clin Cancer Res 18:2199) was used for the experiments outlined below.

[0087] First, a single dose (1.times.10.sup.6 CAR T cells) of IL13(EQ)BB.zeta.+Tcm product was compared to IL13-zetakine CD8+ CTL clones evaluated against day 8 PBT030-2 EGFP:ffuc TS-initiated xenografts (0.1.times.10.sup.6 cells). While both IL13R.alpha.2-specific CAR T cells (IL13-zetakine CTL and IL13(EQ)BB.zeta. Tcm) demonstrated antitumor activity against established PBT030-2 tumors as compared to untreated and mock Tcm (CAR-negative) controls (FIGS. 9A and 9B), IL13(EQ)BB.zeta.+ Tcm mediated significantly improved survival and durable tumor remission with mice living >150 days as compared to our first-generation IL13-zetakine CD8+ CTL clones (FIG. 9C).

[0088] To further compare the therapeutic effectiveness of these two IL13R.alpha.2-CAR T cell products, a dose titration of 1.0, 0.3 and 0.1.times.10.sup.6 CART cells against day 8 PBT030-2 EGFP:ffuc TS-initiated tumors was performed (FIGS. 10A-C). The highest dose (1.times.10.sup.6) of IL13-zetakine CD8+ CTL cl. 2D7 mediated antitumor responses as measured by Xenogen flux in 3 of 6 animals (FIG. 10C), but no significant antitumor responses were observed at lower CAR T cell doses. By comparison, injection of IL13(EQ)BB.zeta.+Tcm product mediated complete tumor regression in the majority of mice at all dose levels, including treatment with as few as 0.1.times.10.sup.6 CAR T cells. These data demonstrate that IL13(EQ)BB.zeta.+Tcm is at least 10-fold more potent than IL13-zetakine CD8+ CTL clones in antitumor efficacy. The improved anti-tumor efficacy of is due to improved T cell persistence in the tumor microenvironment. Evaluation of CD3+ T cells 7-days post i.c. injection revealed significant numbers of IL13(EQ)BB.zeta.+ Tcm in the tumor microenvironment, whereas very few first-generation IL13-zeta CTLs were present (FIG. 11).

Example 9: Comparison of CAR T Cell Delivery Route for Treatment of Large TS-Initiated PBT Tumors

[0089] Described below are studies that compare the route of delivery, intraveneous (i.v.) or intracranial (i.c.), on antitumor activity against invasive primary PBT lines. In pilot studies (data not shown), it was unexpectedly observed that i.v. administered IL13(EQ)BB.zeta.+ Tcm provided no therapeutic benefit as compared to PBS for the treatment of small (day 5) PBT030-2 EGFP:ffLuc tumors. This is in contrast to the robust therapeutic efficacy observed with i.c. administered CAR+ T cells. Reasoning that day 5 PBT030-2 tumors may have been too small to recruit therapeutic T cells from the periphery, a comparison was made of i.v. versus i.c. delivery against larger day 19 PBT030-2 EGFP:ffLuc tumors. For these studies, PBT030-2 engrafted mice were treated with either two i.v. infusions (5.times.10.sup.6 CAR+ Tcm; days 19 and 26) or four i.c. infusions (1.times.10.sup.6 CAR+ Tcm; days 19, 22, 26 and 29) of IL13(EQ)BBZ+ Tcm, or mock Tcm (no CAR). Here too no therapeutic benefit as monitored by Xenogen imaging or Kaplan-Meier survival analysis for i.v. administered CAR+ T cells (FIGS. 12A and 12B). In contrast, potent antitumor activity was observed for i.c. administered IL13(EQ)BB.zeta.+Tcm (FIGS. 12A-B). Next, brains from a cohort of mice 7 days post T cell injection were harvested and evaluated for CD3+ human T cells by IHC. Surprisingly, for mice treated i.v. with either mock Tcm or IL13(EQ)BB.zeta. Tcm there were no detectable CD3+ human T cells in the tumor or in others mouse brain regions where human T cells typically reside (i.e. the leptomeninges) (FIG. 12C), suggesting a deficit in tumor tropism. This is in contrast to the significant number of T cells detected in the i.c. treated mice (FIG. 12D).

[0090] Tumor derived cytokines, particularly MCP-1/CCL2, are important in recruiting T cells to the tumor. Thus, PBT030-2 tumor cells were evaluated and it was found that this line produces high levels of MCP-1/CCL2 comparable to U251T cells (data not shown), a glioma line previously shown to attract i.v. administered effector CD8+ T cells to i.c. engrafted tumors. Malignant gliomas are highly invasive tumors and are often multi-focal in presentation. The studies described above establish that IL13BBZ T.sub.CM can eliminate infiltrated tumors such as PBT030-2, and mediate long-term durable antitumor activity. The capacity of intracranially delivered CAR T cells to traffic to multifocal disease was also examined. For this study PBT030-2 EGFP:ffLuc TSs were implanted in both the left and right hemispheres (FIG. 13A) and CAR+ T cells were injected only at the right tumor site. Encouragingly, for all mice evaluated (n=3) we detected T cells by CD3 IHC 7-days post T cell infusion both at the site of injection (i.e. right tumor), as well within the tumor on the left hemisphere (FIG. 13B). These findings provide evidence that CAR+ T cells are able to traffic to and infiltrate tumor foci at distant sites. Similar findings were also observed in a second tumor model using the U251T glioma cell line (data not shown).

Example 10: Comparison of Costimulatory Domains

[0091] A series of studies were conducted to evaluate various costimulatory domains. The various CAR evaluated are depicted schematically in FIG. 14A and included a first generation CD3.zeta. CAR lacking a costimulatory domain, two second generation CARs incorporating either a 4-1BB costimulatory domain or a CD28 costimulatory domain, and a third generation CAR containing both a CD28 costimulatory domain and 41BB costimulatory domain. All CAR constructs also contain the T2A ribosomal skip sequence and a truncated CD19 (CD19t) sequence as a marker for transduced cells.

[0092] CD4 and CD8 T.sub.CM were lentivirally transduced and CAR-expressing T cells were immunomagnetically enriched via anti-CD19. CD19 and IL13 (i.e., CAR) expression levels as measured by flow cytometry. The results are shown in FIG. 14B. Stability of each CAR construct was determined by dividing the CAR (IL13) mean flourescence intensity (MFI) by that of the transduction marker (CD19t) (FIG. 14C). The two CAR including a 4-1BB costimulatory domain exhibited the lowest expression levels as compared to the CD19t transduction marker.

[0093] The ability of the indicated mock-transduced or CAR-expressing T cells to kill IL13R.alpha.2-expressing PBT030-2 tumor cell targets was determined in a 4-hour .sup.51Cr-release assay at the indicated effector:target ratios. The results of this study are in FIG. 15A (mean % chromium release.+-.S.D. of triplicate wells are depicted). As expected, mock-transduced T cells did not efficiently lyse the targets. In contrast, all CAR-expressing T cells lysed the tumor cells in a similar manner. FIG. 15B depicts the results of a study in which the indicated mock-transduced or CAR-expressing T cells were co-cultured overnight with IL13R.alpha.2-expressing PBT030-2 tumor cells at a 10:1 ratio and supernatants were analyzed for IL-13 and IFN-.gamma. levels by cytometric bead array. Interestingly, T cells expressing the zeta, 41BB-zeta or CD28-41BB-zeta CARs exhibited lower antigen-stimulated cytokine production than T cells expressing the CD28-zeta CAR.

[0094] The in vivo efficacy of the various CAR was examined as follows. Briefly, NSG mice received an intracranial injection of ffLuc+ PBT030-2 tumor cells on day 0, and were randomized into 6 groups (n=9-10 mice per group) for i.c. treatment with either PBS (Tumor Only), mock-transduced T cells or T cells expressing the indicated IL13R.alpha.2-specific CAR on day 8. Quantitative bioluminescence imaging was then carried out to monitor tumor growth over time. Bioluminescence images for representative mice in each group (FIG. 16A). Flux levels for each mouse at Day 27 (FIG. 16B). All groups treated with IL13R.alpha.2-specific CAR T cells, except those treated with T cells expressing the CD28-CAR, show statistically-significant reduction in tumor volume compared to mice treated with mock-transduced T cells (FIG. 16C).

Example 11: Amino acid Sequence of IL13(EQ)BB.zeta./CD19t

[0095] The complete amino acid sequence of IL13(EQ)BB.zeta./CD19t is depicted in FIGS. 17A-B. The entire sequence (SEQ ID NO:1) includes: a 22 amino acid GMCSF signal peptide (SEQ ID NO:2), a 112 amino acid IL-13 sequence (SEQ ID NO:3; amino acid substitution E13Y shown in bold); a 229 amino acid IgG4 sequence (SEQ ID NO:4; with amino acid substitutions L235E and N297Q shown in bold); a 22 amino acid CD4 transmembrane sequence (SEQ ID NO:5); a 42 amino acid 4-1BB sequence (SEQ ID NO:6); a 3 amino acid Gly linker; a 112 amino acid CD3.zeta. sequence (SEQ ID NO:7); a 24 amino acid T2A sequence (SEQ ID NO:8); and a 323 amino acid CD19t sequence (SEQ ID NO:9).

[0096] The mature chimeric antigen receptor sequence (SEQ ID NO:10) includes: a 112 amino acid IL-13 sequence (SEQ ID NO:3; amino acid substitution E13Y shown in bold); a 229 amino acid IgG4 sequence (SEQ ID NO:4; with amino acid substitutions L235E and N297Q shown in bold); at 22 amino acid CD4 sequence (SEQ ID NO:5); a 42 amino acid 4-1BB sequence (SEQ ID NO:6); a 3 amino acid Gly linker; and a 112 amino acid CD3.zeta. sequence (SEQ ID NO:7). Within this CAR sequence (SEQ ID NO:10) is the IL-13/IgG4/CD4t/41-BB sequence (SEQ ID NO:11), which includes: a 112 amino acid IL-13 sequence (SEQ ID NO:3; amino acid substitution E13Y shown in bold); a 229 amino acid IgG4 sequence (SEQ ID NO:4; with amino acid substitutions L235E and N297Q shown in bold); at 22 amino acid CD4 sequence (SEQ ID NO:5); and a 42 amino acid 4-1BB sequence (SEQ ID NO:6). The IL13/IgG4/CD4t/4-1BB sequence (SEQ ID NO:11) can be joined to the 112 amino acid CD3.zeta. sequence (SEQ ID NO:7) by a linker such as a Gly Gly Gly linker. The CAR sequence (SEQ ID NO:10) can be preceded by a 22 amino acid GMCSF signal peptide (SEQ ID NO:2).

[0097] FIGS. 18A-O depicts a comparison of the sequences of IL13(EQ)41BB.zeta.[IL13{EQ}41BK T2A-CD19t_epHIV7; pF02630] (SEQ ID NO:12) and CD19Rop_epHIV7 (pJ01683) (SEQ ID NO:13).

Example 12: Amino Acid Sequence of IL13(EQ)BB.zeta./CD19t

[0098] FIGS. 19-26 depict the amino acid sequences of additional CAR directed against IL13R.alpha.2 in each case the various domains are labelled except for the GlyGlyGly spacer located between certain intracellular domains. Each includes human IL13 with and Glu to Tyr (SEQ ID NO:3; amino acid substitution E13Y shown in highlighted). In the expression vector used to express these CAR, the amino acid sequence expressed can include a 24 amino acid T2A sequence (SEQ ID NO:8); and a 323 amino acid CD19t sequence (SEQ ID NO:9) to permit coordinated expression of a truncated CD19 sequence on the surface of CAR-expressing cells.

[0099] A panel of CAR comprising human IL13(E13Y) domain, a CD28 tm domain, a CD28gg costimulatory domain, a 4-1BB costimulatory domain, and a CD3.zeta. domain CAR backbone and including either a HL (22 amino acids) spacer, a CD8 hinge (48 amino acids) spacer, IgG4-HL-CH3 (129 amino acids) spacer or a IgG4(EQ) (229 amino acids) spacer were tested for their ability to mediate IL13R.alpha.2-specific killing as evaluated in a 72-hour co-culture assay. With the exception of HL (22 amino acids) which appeared to have poor CAR expression in this system, all were active.

Sequence CWU 1

1

541889PRTArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polypeptide" 1Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro1 5 10 15Ala Phe Leu Leu Ile Pro Gly Pro Val Pro Pro Ser Thr Ala Leu Arg 20 25 30Tyr Leu Ile Glu Glu Leu Val Asn Ile Thr Gln Asn Gln Lys Ala Pro 35 40 45Leu Cys Asn Gly Ser Met Val Trp Ser Ile Asn Leu Thr Ala Gly Met 50 55 60Tyr Cys Ala Ala Leu Glu Ser Leu Ile Asn Val Ser Gly Cys Ser Ala65 70 75 80Ile Glu Lys Thr Gln Arg Met Leu Ser Gly Phe Cys Pro His Lys Val 85 90 95Ser Ala Gly Gln Phe Ser Ser Leu His Val Arg Asp Thr Lys Ile Glu 100 105 110Val Ala Gln Phe Val Lys Asp Leu Leu Leu His Leu Lys Lys Leu Phe 115 120 125Arg Glu Gly Arg Phe Asn Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro 130 135 140Cys Pro Ala Pro Glu Phe Glu Gly Gly Pro Ser Val Phe Leu Phe Pro145 150 155 160Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr 165 170 175Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn 180 185 190Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg 195 200 205Glu Glu Gln Phe Gln Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val 210 215 220Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser225 230 235 240Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys 245 250 255Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu 260 265 270Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe 275 280 285Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu 290 295 300Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe305 310 315 320Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly 325 330 335Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr 340 345 350Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys Met Ala Leu Ile Val 355 360 365Leu Gly Gly Val Ala Gly Leu Leu Leu Phe Ile Gly Leu Gly Ile Phe 370 375 380Phe Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe385 390 395 400Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg 405 410 415Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Gly Gly Gly Arg Val 420 425 430Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn 435 440 445Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val 450 455 460Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg465 470 475 480Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys 485 490 495Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg 500 505 510Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys 515 520 525Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg Leu Glu 530 535 540Gly Gly Gly Glu Gly Arg Gly Ser Leu Leu Thr Cys Gly Asp Val Glu545 550 555 560Glu Asn Pro Gly Pro Arg Met Pro Pro Pro Arg Leu Leu Phe Phe Leu 565 570 575Leu Phe Leu Thr Pro Met Glu Val Arg Pro Glu Glu Pro Leu Val Val 580 585 590Lys Val Glu Glu Gly Asp Asn Ala Val Leu Gln Cys Leu Lys Gly Thr 595 600 605Ser Asp Gly Pro Thr Gln Gln Leu Thr Trp Ser Arg Glu Ser Pro Leu 610 615 620Lys Pro Phe Leu Lys Leu Ser Leu Gly Leu Pro Gly Leu Gly Ile His625 630 635 640Met Arg Pro Leu Ala Ile Trp Leu Phe Ile Phe Asn Val Ser Gln Gln 645 650 655Met Gly Gly Phe Tyr Leu Cys Gln Pro Gly Pro Pro Ser Glu Lys Ala 660 665 670Trp Gln Pro Gly Trp Thr Val Asn Val Glu Gly Ser Gly Glu Leu Phe 675 680 685Arg Trp Asn Val Ser Asp Leu Gly Gly Leu Gly Cys Gly Leu Lys Asn 690 695 700Arg Ser Ser Glu Gly Pro Ser Ser Pro Ser Gly Lys Leu Met Ser Pro705 710 715 720Lys Leu Tyr Val Trp Ala Lys Asp Arg Pro Glu Ile Trp Glu Gly Glu 725 730 735Pro Pro Cys Val Pro Pro Arg Asp Ser Leu Asn Gln Ser Leu Ser Gln 740 745 750Asp Leu Thr Met Ala Pro Gly Ser Thr Leu Trp Leu Ser Cys Gly Val 755 760 765Pro Pro Asp Ser Val Ser Arg Gly Pro Leu Ser Trp Thr His Val His 770 775 780Pro Lys Gly Pro Lys Ser Leu Leu Ser Leu Glu Leu Lys Asp Asp Arg785 790 795 800Pro Ala Arg Asp Met Trp Val Met Glu Thr Gly Leu Leu Leu Pro Arg 805 810 815Ala Thr Ala Gln Asp Ala Gly Lys Tyr Tyr Cys His Arg Gly Asn Leu 820 825 830Thr Met Ser Phe His Leu Glu Ile Thr Ala Arg Pro Val Leu Trp His 835 840 845Trp Leu Leu Arg Thr Gly Gly Trp Lys Val Ser Ala Val Thr Leu Ala 850 855 860Tyr Leu Ile Phe Cys Leu Cys Ser Leu Val Gly Ile Leu His Leu Gln865 870 875 880Arg Ala Leu Val Leu Arg Arg Lys Arg 885222PRTArtificial Sequencesource/note="Description of Artificial Sequence Synthetic peptide" 2Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro1 5 10 15Ala Phe Leu Leu Ile Pro 203112PRTArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polypeptide" 3Gly Pro Val Pro Pro Ser Thr Ala Leu Arg Tyr Leu Ile Glu Glu Leu1 5 10 15Val Asn Ile Thr Gln Asn Gln Lys Ala Pro Leu Cys Asn Gly Ser Met 20 25 30Val Trp Ser Ile Asn Leu Thr Ala Gly Met Tyr Cys Ala Ala Leu Glu 35 40 45Ser Leu Ile Asn Val Ser Gly Cys Ser Ala Ile Glu Lys Thr Gln Arg 50 55 60Met Leu Ser Gly Phe Cys Pro His Lys Val Ser Ala Gly Gln Phe Ser65 70 75 80Ser Leu His Val Arg Asp Thr Lys Ile Glu Val Ala Gln Phe Val Lys 85 90 95Asp Leu Leu Leu His Leu Lys Lys Leu Phe Arg Glu Gly Arg Phe Asn 100 105 1104229PRTArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polypeptide" 4Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe1 5 10 15Glu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 20 25 30Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 35 40 45Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val 50 55 60Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Gln Ser65 70 75 80Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 85 90 95Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser 100 105 110Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 115 120 125Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln 130 135 140Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala145 150 155 160Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 165 170 175Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu 180 185 190Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser 195 200 205Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 210 215 220Leu Ser Leu Gly Lys225522PRTHomo sapiens 5Met Ala Leu Ile Val Leu Gly Gly Val Ala Gly Leu Leu Leu Phe Ile1 5 10 15Gly Leu Gly Ile Phe Phe 20642PRTArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polypeptide" 6Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met1 5 10 15Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe 20 25 30Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu 35 407112PRTArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polypeptide" 7Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly1 5 10 15Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr 20 25 30Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys 35 40 45Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys 50 55 60Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg65 70 75 80Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala 85 90 95Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg 100 105 110824PRTArtificial Sequencesource/note="Description of Artificial Sequence Synthetic peptide" 8Leu Glu Gly Gly Gly Glu Gly Arg Gly Ser Leu Leu Thr Cys Gly Asp1 5 10 15Val Glu Glu Asn Pro Gly Pro Arg 209323PRTArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polypeptide" 9Met Pro Pro Pro Arg Leu Leu Phe Phe Leu Leu Phe Leu Thr Pro Met1 5 10 15Glu Val Arg Pro Glu Glu Pro Leu Val Val Lys Val Glu Glu Gly Asp 20 25 30Asn Ala Val Leu Gln Cys Leu Lys Gly Thr Ser Asp Gly Pro Thr Gln 35 40 45Gln Leu Thr Trp Ser Arg Glu Ser Pro Leu Lys Pro Phe Leu Lys Leu 50 55 60Ser Leu Gly Leu Pro Gly Leu Gly Ile His Met Arg Pro Leu Ala Ile65 70 75 80Trp Leu Phe Ile Phe Asn Val Ser Gln Gln Met Gly Gly Phe Tyr Leu 85 90 95Cys Gln Pro Gly Pro Pro Ser Glu Lys Ala Trp Gln Pro Gly Trp Thr 100 105 110Val Asn Val Glu Gly Ser Gly Glu Leu Phe Arg Trp Asn Val Ser Asp 115 120 125Leu Gly Gly Leu Gly Cys Gly Leu Lys Asn Arg Ser Ser Glu Gly Pro 130 135 140Ser Ser Pro Ser Gly Lys Leu Met Ser Pro Lys Leu Tyr Val Trp Ala145 150 155 160Lys Asp Arg Pro Glu Ile Trp Glu Gly Glu Pro Pro Cys Val Pro Pro 165 170 175Arg Asp Ser Leu Asn Gln Ser Leu Ser Gln Asp Leu Thr Met Ala Pro 180 185 190Gly Ser Thr Leu Trp Leu Ser Cys Gly Val Pro Pro Asp Ser Val Ser 195 200 205Arg Gly Pro Leu Ser Trp Thr His Val His Pro Lys Gly Pro Lys Ser 210 215 220Leu Leu Ser Leu Glu Leu Lys Asp Asp Arg Pro Ala Arg Asp Met Trp225 230 235 240Val Met Glu Thr Gly Leu Leu Leu Pro Arg Ala Thr Ala Gln Asp Ala 245 250 255Gly Lys Tyr Tyr Cys His Arg Gly Asn Leu Thr Met Ser Phe His Leu 260 265 270Glu Ile Thr Ala Arg Pro Val Leu Trp His Trp Leu Leu Arg Thr Gly 275 280 285Gly Trp Lys Val Ser Ala Val Thr Leu Ala Tyr Leu Ile Phe Cys Leu 290 295 300Cys Ser Leu Val Gly Ile Leu His Leu Gln Arg Ala Leu Val Leu Arg305 310 315 320Arg Lys Arg10520PRTArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polypeptide" 10Gly Pro Val Pro Pro Ser Thr Ala Leu Arg Tyr Leu Ile Glu Glu Leu1 5 10 15Val Asn Ile Thr Gln Asn Gln Lys Ala Pro Leu Cys Asn Gly Ser Met 20 25 30Val Trp Ser Ile Asn Leu Thr Ala Gly Met Tyr Cys Ala Ala Leu Glu 35 40 45Ser Leu Ile Asn Val Ser Gly Cys Ser Ala Ile Glu Lys Thr Gln Arg 50 55 60Met Leu Ser Gly Phe Cys Pro His Lys Val Ser Ala Gly Gln Phe Ser65 70 75 80Ser Leu His Val Arg Asp Thr Lys Ile Glu Val Ala Gln Phe Val Lys 85 90 95Asp Leu Leu Leu His Leu Lys Lys Leu Phe Arg Glu Gly Arg Phe Asn 100 105 110Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe 115 120 125Glu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 130 135 140Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val145 150 155 160Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val 165 170 175Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Gln Ser 180 185 190Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 195 200 205Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser 210 215 220Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro225 230 235 240Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln 245 250 255Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 260 265 270Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 275 280 285Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu 290 295 300Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser305 310 315 320Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 325 330 335Leu Ser Leu Gly Lys Met Ala Leu Ile Val Leu Gly Gly Val Ala Gly 340 345 350Leu Leu Leu Phe Ile Gly Leu Gly Ile Phe Phe Lys Arg Gly Arg Lys 355 360 365Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln Thr 370 375 380Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu385 390 395 400Gly Gly Cys Glu Leu Gly Gly Gly Arg Val Lys Phe Ser Arg Ser Ala 405 410 415Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu 420 425 430Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly 435 440 445Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu 450 455 460Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser465 470 475 480Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly 485 490 495Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu 500 505 510His Met Gln Ala Leu Pro Pro Arg 515 52011405PRTArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polypeptide" 11Gly Pro Val Pro Pro Ser Thr Ala Leu Arg Tyr Leu Ile Glu Glu Leu1 5 10 15Val Asn Ile Thr Gln Asn Gln Lys Ala Pro Leu Cys Asn Gly

Ser Met 20 25 30Val Trp Ser Ile Asn Leu Thr Ala Gly Met Tyr Cys Ala Ala Leu Glu 35 40 45Ser Leu Ile Asn Val Ser Gly Cys Ser Ala Ile Glu Lys Thr Gln Arg 50 55 60Met Leu Ser Gly Phe Cys Pro His Lys Val Ser Ala Gly Gln Phe Ser65 70 75 80Ser Leu His Val Arg Asp Thr Lys Ile Glu Val Ala Gln Phe Val Lys 85 90 95Asp Leu Leu Leu His Leu Lys Lys Leu Phe Arg Glu Gly Arg Phe Asn 100 105 110Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe 115 120 125Glu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 130 135 140Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val145 150 155 160Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val 165 170 175Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Gln Ser 180 185 190Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 195 200 205Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser 210 215 220Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro225 230 235 240Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln 245 250 255Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 260 265 270Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 275 280 285Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu 290 295 300Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser305 310 315 320Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 325 330 335Leu Ser Leu Gly Lys Met Ala Leu Ile Val Leu Gly Gly Val Ala Gly 340 345 350Leu Leu Leu Phe Ile Gly Leu Gly Ile Phe Phe Lys Arg Gly Arg Lys 355 360 365Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln Thr 370 375 380Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu385 390 395 400Gly Gly Cys Glu Leu 405127754DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polynucleotide" 12gttagaccag atctgagcct gggagctctc tggctaacta gggaacccac tgcttaagcc 60tcaataaagc ttgccttgag tgcttcaagt agtgtgtgcc cgtctgttgt gtgactctgg 120taactagaga tccctcagac ccttttagtc agtgtggaaa atctctagca gtggcgcccg 180aacagggact tgaaagcgaa agggaaacca gaggagctct ctcgacgcag gactcggctt 240gctgaagcgc gcacggcaag aggcgagggg cggcgactgg tgagtacgcc aaaaattttg 300actagcggag gctagaagga gagagatggg tgcgagagcg tcagtattaa gcgggggaga 360attagatcga tgggaaaaaa ttcggttaag gccaggggga aagaaaaaat ataaattaaa 420acatatagta tgggcaagca gggagctaga acgattcgca gttaatcctg gcctgttaga 480aacatcagaa ggctgtagac aaatactggg acagctacaa ccatcccttc agacaggatc 540agaagaactt agatcattat ataatacagt agcaaccctc tattgtgtgc atcaaaggat 600agagataaaa gacaccaagg aagctttaga caagatagag gaagagcaaa acaaaagtaa 660gaaaaaagca cagcaagcag cagctgacac aggacacagc aatcaggtca gccaaaatta 720ccctatagtg cagaacatcc aggggcaaat ggtacatcag gccatatcac ctagaacttt 780aaatgcatgg gtaaaagtag tagaagagaa ggctttcagc ccagaagtga tacccatgtt 840ttcagcatta tcagaaggag ccaccccaca agatttaaac accatgctaa acacagtggg 900gggacatcaa gcagccatgc aaatgttaaa agagaccatc aatgaggaag ctgcaggcaa 960agagaagagt ggtgcagaga gaaaaaagag cagtgggaat aggagctttg ttccttgggt 1020tcttgggagc agcaggaagc actatgggcg cagcgtcaat gacgctgacg gtacaggcca 1080gacaattatt gtctggtata gtgcagcagc agaacaattt gctgagggct attgaggcgc 1140aacagcatct gttgcaactc acagtctggg gcatcaagca gctccaggca agaatcctgg 1200ctgtggaaag atacctaaag gatcaacagc tcctggggat ttggggttgc tctggaaaac 1260tcatttgcac cactgctgtg ccttggatct acaaatggca gtattcatcc acaattttaa 1320aagaaaaggg gggattgggg ggtacagtgc aggggaaaga atagtagaca taatagcaac 1380agacatacaa actaaagaat tacaaaaaca aattacaaaa attcaaaatt ttcgggttta 1440ttacagggac agcagagatc cagtttgggg atcaattgca tgaagaatct gcttagggtt 1500aggcgttttg cgctgcttcg cgaggatctg cgatcgctcc ggtgcccgtc agtgggcaga 1560gcgcacatcg cccacagtcc ccgagaagtt ggggggaggg gtcggcaatt gaaccggtgc 1620ctagagaagg tggcgcgggg taaactggga aagtgatgtc gtgtactggc tccgcctttt 1680tcccgagggt gggggagaac cgtatataag tgcagtagtc gccgtgaacg ttctttttcg 1740caacgggttt gccgccagaa cacagctgaa gcttcgaggg gctcgcatct ctccttcacg 1800cgcccgccgc cctacctgag gccgccatcc acgccggttg agtcgcgttc tgccgcctcc 1860cgcctgtggt gcctcctgaa ctgcgtccgc cgtctaggta agtttaaagc tcaggtcgag 1920accgggcctt tgtccggcgc tcccttggag cctacctaga ctcagccggc tctccacgct 1980ttgcctgacc ctgcttgctc aactctacgt ctttgtttcg ttttctgttc tgcgccgtta 2040cagatccaag ctgtgaccgg cgcctacggc tagcgccgcc accatgctgc tgctggtgac 2100cagcctgctg ctgtgcgagc tgccccaccc cgcctttctg ctgatccctg gccccgtgcc 2160ccctagcacc gccctgcgct acctgatcga ggaactggtg aacatcaccc agaaccagaa 2220agcccccctg tgcaacggca gcatggtgtg gagcatcaac ctgaccgccg gcatgtactg 2280tgccgccctg gaaagcctga tcaacgtgag cggctgcagc gccatcgaga aaacccagcg 2340gatgctgtcc ggcttctgcc cccacaaggt gtccgccgga cagttcagca gcctgcacgt 2400gcgggacacc aagatcgagg tggcccagtt cgtgaaggac ctgctgctgc acctgaagaa 2460gctgttccgg gagggccggt tcaactacaa gaccaccccc cctgtgctgg acagcgacgg 2520cagcttcttc ctgtacagca ggctgaccgt ggacaagagc cggtggcagg aaggcaacgt 2580ctttagctgc agcgtgatgc acgaggccct gcacaaccac tacacccaga agagcctgtc 2640cctgagcctg ggcaagcggg tgaagttcag ccggtccgcc gacgcccctg cctaccagca 2700gggccagaac cagctgtaca acgagctgaa cctgggcagg cgggaggaat acgacgtgct 2760ggacaagcgg agaggccggg accctgagat gggcggcaag cctcggcgga agaaccccca 2820ggaaggcctg tataacgaac tgcagaaaga caagatggcc gaggcctaca gcgagatcgg 2880catgaagggc gagcggaggc ggggcaaggg ccacgacggc ctgtatcagg gcctgtccac 2940cgccaccaag gatacctacg acgccctgca catgcaggcc ctgcccccaa ggtctagacc 3000cgggctgcag gaattcgata tcaagcttat cgataatcaa cctctggatt acaaaatttg 3060tgaaagattg actggtattc ttaactatgt tgctcctttt acgctatgtg gatacgctgc 3120tttaatgcct ttgtatcatg ctattgcttc ccgtatggct ttcattttct cctccttgta 3180taaatcctgg ttgctgtctc tttatgagga gttgtggccc gttgtcaggc aacgtggcgt 3240ggtgtgcact gtgtttgctg acgcaacccc cactggttgg ggcattgcca ccacctgtca 3300gctcctttcc gggactttcg ctttccccct ccctattgcc acggcggaac tcatcgccgc 3360ctgccttgcc cgctgctgga caggggctcg gctgttgggc actgacaatt ccgtggtgtt 3420gtcggggaaa tcatcgtcct ttccttggct gctcgcctgt gttgccacct ggattctgcg 3480cgggacgtcc ttctgctacg tcccttcggc cctcaatcca gcggaccttc cttcccgcgg 3540cctgctgccg gctctgcggc ctcttccgcg tcttcgcctt cgccctcaga cgagtcggat 3600ctccctttgg gccgcctccc cgcatcgata ccgtcgacta gccgtacctt taagaccaat 3660gacttacaag gcagctgtag atcttagcca ctttttaaaa gaaaaggggg gactggaagg 3720gctaattcac tcccaaagaa gacaagatct gctttttgcc tgtactgggt ctctctggtt 3780agaccagatc tgagcctggg agctctctgg ctaactaggg aacccactgc ttaagcctca 3840ataaagcttg ccttgagtgc ttcaagtagt gtgtgcccgt ctgttgtgtg actctggtaa 3900ctagagatcc ctcagaccct tttagtcagt gtggaaaatc tctagcagaa ttcgatatca 3960agcttatcga taccgtcgac ctcgaggggg ggcccggtac ccaattcgcc ctatagtgag 4020tcgtattaca attcactggc cgtcgtttta caacgtcgtg actgggaaaa ccctggcgtt 4080acccaactta atcgccttgc agcacatccc cctttcgcca gctggcgtaa tagcgaagag 4140gcccgcaccg atcgcccttc ccaacagttg cgcagcctga atggcgaatg gaaattgtaa 4200gcgttaatat tttgttaaaa ttcgcgttaa atttttgtta aatcagctca ttttttaacc 4260aataggccga aatcggcaaa atcccttata aatcaaaaga atagaccgag atagggttga 4320gtgttgttcc agtttggaac aagagtccac tattaaagaa cgtggactcc aacgtcaaag 4380ggcgaaaaac cgtctatcag ggcgatggcc cactacgtga accatcaccc taatcaagtt 4440ttttggggtc gaggtgccgt aaagcactaa atcggaaccc taaagggagc ccccgattta 4500gagcttgacg gggaaagccg gcgaacgtgg cgagaaagga agggaagaaa gcgaaaggag 4560cgggcgctag ggcgctggca agtgtagcgg tcacgctgcg cgtaaccacc acacccgccg 4620cgcttaatgc gccgctacag ggcgcgtcag gtggcacttt tcggggaaat gtgcgcggaa 4680cccctatttg tttatttttc taaatacatt caaatatgta tccgctcatg agacaataac 4740cctgataaat gcttcaataa tattgaaaaa ggaagagtat gagtattcaa catttccgtg 4800tcgcccttat tccctttttt gcggcatttt gccttcctgt ttttgctcac ccagaaacgc 4860tggtgaaagt aaaagatgct gaagatcagt tgggtgcacg agtgggttac atcgaactgg 4920atctcaacag cggtaagatc cttgagagtt ttcgccccga agaacgtttt ccaatgatga 4980gcacttttaa agttctgcta tgtggcgcgg tattatcccg tattgacgcc gggcaagagc 5040aactcggtcg ccgcatacac tattctcaga atgacttggt tgagtactca ccagtcacag 5100aaaagcatct tacggatggc atgacagtaa gagaattatg cagtgctgcc ataaccatga 5160gtgataacac tgcggccaac ttacttctga caacgatcgg aggaccgaag gagctaaccg 5220cttttttgca caacatgggg gatcatgtaa ctcgccttga tcgttgggaa ccggagctga 5280atgaagccat accaaacgac gagcgtgaca ccacgatgcc tgtagcaatg gcaacaacgt 5340tgcgcaaact attaactggc gaactactta ctctagcttc ccggcaacaa ttaatagact 5400ggatggaggc ggataaagtt gcaggaccac ttctgcgctc ggcccttccg gctggctggt 5460ttattgctga taaatctgga gccggtgagc gtgggtctcg cggtatcatt gcagcactgg 5520ggccagatgg taagccctcc cgtatcgtag ttatctacac gacggggagt caggcaacta 5580tggatgaacg aaatagacag atcgctgaga taggtgcctc actgattaag cattggtaac 5640tgtcagacca agtttactca tatatacttt agattgattt aaaacttcat ttttaattta 5700aaaggatcta ggtgaagatc ctttttgata atctcatgac caaaatccct taacgtgagt 5760tttcgttcca ctgagcgtca gaccccgtag aaaagatcaa aggatcttct tgagatcctt 5820tttttctgcg cgtaatctgc tgcttgcaaa caaaaaaacc accgctacca gcggtggttt 5880gtttgccgga tcaagagcta ccaactcttt ttccgaaggt aactggcttc agcagagcgc 5940agataccaaa tactgttctt ctagtgtagc cgtagttagg ccaccacttc aagaactctg 6000tagcaccgcc tacatacctc gctctgctaa tcctgttacc agtggctgct gccagtggcg 6060ataagtcgtg tcttaccggg ttggactcaa gacgatagtt accggataag gcgcagcggt 6120cgggctgaac ggggggttcg tgcacacagc ccagcttgga gcgaacgacc tacaccgaac 6180tgagatacct acagcgtgag ctatgagaaa gcgccacgct tcccgaaggg agaaaggcgg 6240acaggtatcc ggtaagcggc agggtcggaa caggagagcg cacgagggag cttccagggg 6300gaaacgcctg gtatctttat agtcctgtcg ggtttcgcca cctctgactt gagcgtcgat 6360ttttgtgatg ctcgtcaggg gggcggagcc tatggaaaaa cgccagcaac gcggcctttt 6420tacggttcct ggccttttgc tggccttttg ctcacatgtt ctttcctgcg ttatcccctg 6480attctgtgga taaccgtatt accgcctttg agtgagctga taccgctcgc cgcagccgaa 6540cgaccgagcg cagcgagtca gtgagcgagg aagcggaaga gcgcccaata cgcaaaccgc 6600ctctccccgc gcgttggccg attcattaat gcagctggca cgacaggttt cccgactgga 6660aagcgggcag tgagcgcaac gcaattaatg tgagttagct cactcattag gcaccccagg 6720ctttacactt tatgcttccg gctcgtatgt tgtgtggaat tgtgagcgga taacaatttc 6780acacaggaaa cagctatgac catgattacg ccaagctcga aattaaccct cactaaaggg 6840aacaaaagct ggagctccac cgcggtggcg gcctcgaggt cgagatccgg tcgaccagca 6900accatagtcc cgcccctaac tccgcccatc ccgcccctaa ctccgcccag ttccgcccat 6960tctccgcccc atggctgact aatttttttt atttatgcag aggccgaggc cgcctcggcc 7020tctgagctat tccagaagta gtgaggaggc ttttttggag gcctaggctt ttgcaaaaag 7080cttcgacggt atcgattggc tcatgtccaa cattaccgcc atgttgacat tgattattga 7140ctagttatta atagtaatca attacggggt cattagttca tagcccatat atggagttcc 7200gcgttacata acttacggta aatggcccgc ctggctgacc gcccaacgac ccccgcccat 7260tgacgtcaat aatgacgtat gttcccatag taacgccaat agggactttc cattgacgtc 7320aatgggtgga gtatttacgg taaactgccc acttggcagt acatcaagtg tatcatatgc 7380caagtacgcc ccctattgac gtcaatgacg gtaaatggcc cgcctggcat tatgcccagt 7440acatgacctt atgggacttt cctacttggc agtacatcta cgtattagtc atcgctatta 7500ccatggtgat gcggttttgg cagtacatca atgggcgtgg atagcggttt gactcacggg 7560gatttccaag tctccacccc attgacgtca atgggagttt gttttggcac caaaatcaac 7620gggactttcc aaaatgtcgt aacaactccg ccccattgac gcaaatgggc ggtaggcgtg 7680tacggaattc ggagtggcga gccctcagat cctgcatata agcagctgct ttttgcctgt 7740actgggtctc tctg 7754138732DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polynucleotide" 13gttagaccag atctgagcct gggagctctc tggctaacta gggaacccac tgcttaagcc 60tcaataaagc ttgccttgag tgcttcaagt agtgtgtgcc cgtctgttgt gtgactctgg 120taactagaga tccctcagac ccttttagtc agtgtggaaa atctctagca gtggcgcccg 180aacagggact tgaaagcgaa agggaaacca gaggagctct ctcgacgcag gactcggctt 240gctgaagcgc gcacggcaag aggcgagggg cggcgactgg tgagtacgcc aaaaattttg 300actagcggag gctagaagga gagagatggg tgcgagagcg tcagtattaa gcgggggaga 360attagatcga tgggaaaaaa ttcggttaag gccaggggga aagaaaaaat ataaattaaa 420acatatagta tgggcaagca gggagctaga acgattcgca gttaatcctg gcctgttaga 480aacatcagaa ggctgtagac aaatactggg acagctacaa ccatcccttc agacaggatc 540agaagaactt agatcattat ataatacagt agcaaccctc tattgtgtgc atcaaaggat 600agagataaaa gacaccaagg aagctttaga caagatagag gaagagcaaa acaaaagtaa 660gaaaaaagca cagcaagcag cagctgacac aggacacagc aatcaggtca gccaaaatta 720ccctatagtg cagaacatcc aggggcaaat ggtacatcag gccatatcac ctagaacttt 780aaatgcatgg gtaaaagtag tagaagagaa ggctttcagc ccagaagtga tacccatgtt 840ttcagcatta tcagaaggag ccaccccaca agatttaaac accatgctaa acacagtggg 900gggacatcaa gcagccatgc aaatgttaaa agagaccatc aatgaggaag ctgcaggcaa 960agagaagagt ggtgcagaga gaaaaaagag cagtgggaat aggagctttg ttccttgggt 1020tcttgggagc agcaggaagc actatgggcg cagcgtcaat gacgctgacg gtacaggcca 1080gacaattatt gtctggtata gtgcagcagc agaacaattt gctgagggct attgaggcgc 1140aacagcatct gttgcaactc acagtctggg gcatcaagca gctccaggca agaatcctgg 1200ctgtggaaag atacctaaag gatcaacagc tcctggggat ttggggttgc tctggaaaac 1260tcatttgcac cactgctgtg ccttggatct acaaatggca gtattcatcc acaattttaa 1320aagaaaaggg gggattgggg ggtacagtgc aggggaaaga atagtagaca taatagcaac 1380agacatacaa actaaagaat tacaaaaaca aattacaaaa attcaaaatt ttcgggttta 1440ttacagggac agcagagatc cagtttgggg atcaattgca tgaagaatct gcttagggtt 1500aggcgttttg cgctgcttcg cgaggatctg cgatcgctcc ggtgcccgtc agtgggcaga 1560gcgcacatcg cccacagtcc ccgagaagtt ggggggaggg gtcggcaatt gaaccggtgc 1620ctagagaagg tggcgcgggg taaactggga aagtgatgtc gtgtactggc tccgcctttt 1680tcccgagggt gggggagaac cgtatataag tgcagtagtc gccgtgaacg ttctttttcg 1740caacgggttt gccgccagaa cacagctgaa gcttcgaggg gctcgcatct ctccttcacg 1800cgcccgccgc cctacctgag gccgccatcc acgccggttg agtcgcgttc tgccgcctcc 1860cgcctgtggt gcctcctgaa ctgcgtccgc cgtctaggta agtttaaagc tcaggtcgag 1920accgggcctt tgtccggcgc tcccttggag cctacctaga ctcagccggc tctccacgct 1980ttgcctgacc ctgcttgctc aactctacgt ctttgtttcg ttttctgttc tgcgccgtta 2040cagatccaag ctgtgaccgg cgcctacggc tagcgccgcc accatgctgc tgctggtgac 2100cagcctgctg ctgtgcgagc tgccccaccc cgcctttctg ctgatccccg acatccagat 2160gacccagacc acctccagcc tgagcgccag cctgggcgac cgggtgacca tcagctgccg 2220ggccagccag gacatcagca agtacctgaa ctggtatcag cagaagcccg acggcaccgt 2280caagctgctg atctaccaca ccagccggct gcacagcggc gtgcccagcc ggtttagcgg 2340cagcggctcc ggcaccgact acagcctgac catctccaac ctggaacagg aagatatcgc 2400cacctacttt tgccagcagg gcaacacact gccctacacc tttggcggcg gaacaaagct 2460ggaaatcacc ggcagcacct ccggcagcgg caagcctggc agcggcgagg gcagcaccaa 2520gggcgaggtg aagctgcagg aaagcggccc tggcctggtg gcccccagcc agagcctgag 2580cgtgacctgc accgtgagcg gcgtgagcct gcccgactac ggcgtgagct ggatccggca 2640gccccccagg aagggcctgg aatggctggg cgtgatctgg ggcagcgaga ccacctacta 2700caacagcgcc ctgaagagcc ggctgaccat catcaaggac aacagcaaga gccaggtgtt 2760cctgaagatg aacagcctgc agaccgacga caccgccatc tactactgcg ccaagcacta 2820ctactacggc ggcagctacg ccatggacta ctggggccag ggcaccagcg tgaccgtgag 2880cagcgagagc aagtacggcc ctccctgccc cccttgccct gcccccgagt tcctgggcgg 2940acccagcgtg ttcctgttcc cccccaagcc caaggacacc ctgatgatca gccggacccc 3000cgaggtgacc tgcgtggtgg tggacgtgag ccaggaagat cccgaggtcc agttcaattg 3060gtacgtggac ggcgtggagg tgcacaacgc caagaccaag cccagggaag agcagttcaa 3120cagcacctac cgggtggtgt ccgtgctgac cgtgctgcac caggactggc tgaacggcaa 3180agaatacaag tgcaaggtgt ccaacaaggg cctgcccagc agcatcgaga aaaccatcag 3240caaggccaag ggccagcctc gggagcccca ggtgtacacc ctgccccctt cccaggaaga 3300gatgaccaag aatcaggtgt ccctgacctg cctggtgaag ggcttctacc ccagcgacat 3360cgccgtggag tgggagagca acggccagcc cgagaacaac tacaagacca ccccccctgt 3420gctggacagc gacggcagct tcttcctgta cagcaggctg accgtggaca agagccggtg 3480gcaggaaggc aacgtcttta gctgcagcgt gatgcacgag gccctgcaca accactacac 3540ccagaagagc ctgtccctga gcctgggcaa gatggccctg atcgtgctgg gcggcgtggc 3600cgggctgctg ctgttcatcg gcctgggcat ctttttccgg gtgaagttca gccggtccgc 3660cgacgcccct gcctaccagc agggccagaa ccagctgtac aacgagctga acctgggcag 3720gcgggaggaa tacgacgtgc tggacaagcg gagaggccgg gaccctgaga tgggcggcaa 3780gcccaggcgg aagaaccctc aggaaggcct gtataacgaa ctgcagaaag acaagatggc 3840cgaggcctac agcgagatcg gcatgaaggg cgagcggcgg aggggcaagg gccacgacgg 3900cctgtaccag ggcctgagca ccgccaccaa ggatacctac gacgccctgc acatgcaggc 3960cctgcccccc aggtgacccg ggctgcagga attcgatatc aagcttatcg ataatcaacc 4020tctggattac aaaatttgtg aaagattgac tggtattctt aactatgttg ctccttttac 4080gctatgtgga tacgctgctt taatgccttt gtatcatgct attgcttccc gtatggcttt 4140cattttctcc tccttgtata aatcctggtt gctgtctctt tatgaggagt tgtggcccgt 4200tgtcaggcaa cgtggcgtgg tgtgcactgt gtttgctgac gcaaccccca ctggttgggg 4260cattgccacc acctgtcagc tcctttccgg gactttcgct ttccccctcc ctattgccac 4320ggcggaactc atcgccgcct gccttgcccg ctgctggaca ggggctcggc tgttgggcac 4380tgacaattcc gtggtgttgt cggggaaatc atcgtccttt ccttggctgc tcgcctgtgt 4440tgccacctgg attctgcgcg ggacgtcctt ctgctacgtc ccttcggccc tcaatccagc 4500ggaccttcct tcccgcggcc tgctgccggc tctgcggcct cttccgcgtc ttcgccttcg 4560ccctcagacg agtcggatct ccctttgggc cgcctccccg catcgatacc gtcgactagc 4620cgtaccttta agaccaatga cttacaaggc agctgtagat cttagccact ttttaaaaga 4680aaagggggga ctggaagggc taattcactc ccaaagaaga caagatctgc tttttgcctg 4740tactgggtct

ctctggttag accagatctg agcctgggag ctctctggct aactagggaa 4800cccactgctt aagcctcaat aaagcttgcc ttgagtgctt caagtagtgt gtgcccgtct 4860gttgtgtgac tctggtaact agagatccct cagacccttt tagtcagtgt ggaaaatctc 4920tagcagaatt cgatatcaag cttatcgata ccgtcgacct cgaggggggg cccggtaccc 4980aattcgccct atagtgagtc gtattacaat tcactggccg tcgttttaca acgtcgtgac 5040tgggaaaacc ctggcgttac ccaacttaat cgccttgcag cacatccccc tttcgccagc 5100tggcgtaata gcgaagaggc ccgcaccgat cgcccttccc aacagttgcg cagcctgaat 5160ggcgaatgga aattgtaagc gttaatattt tgttaaaatt cgcgttaaat ttttgttaaa 5220tcagctcatt ttttaaccaa taggccgaaa tcggcaaaat cccttataaa tcaaaagaat 5280agaccgagat agggttgagt gttgttccag tttggaacaa gagtccacta ttaaagaacg 5340tggactccaa cgtcaaaggg cgaaaaaccg tctatcaggg cgatggccca ctacgtgaac 5400catcacccta atcaagtttt ttggggtcga ggtgccgtaa agcactaaat cggaacccta 5460aagggagccc ccgatttaga gcttgacggg gaaagccggc gaacgtggcg agaaaggaag 5520ggaagaaagc gaaaggagcg ggcgctaggg cgctggcaag tgtagcggtc acgctgcgcg 5580taaccaccac acccgccgcg cttaatgcgc cgctacaggg cgcgtcaggt ggcacttttc 5640ggggaaatgt gcgcggaacc cctatttgtt tatttttcta aatacattca aatatgtatc 5700cgctcatgag acaataaccc tgataaatgc ttcaataata ttgaaaaagg aagagtatga 5760gtattcaaca tttccgtgtc gcccttattc ccttttttgc ggcattttgc cttcctgttt 5820ttgctcaccc agaaacgctg gtgaaagtaa aagatgctga agatcagttg ggtgcacgag 5880tgggttacat cgaactggat ctcaacagcg gtaagatcct tgagagtttt cgccccgaag 5940aacgttttcc aatgatgagc acttttaaag ttctgctatg tggcgcggta ttatcccgta 6000ttgacgccgg gcaagagcaa ctcggtcgcc gcatacacta ttctcagaat gacttggttg 6060agtactcacc agtcacagaa aagcatctta cggatggcat gacagtaaga gaattatgca 6120gtgctgccat aaccatgagt gataacactg cggccaactt acttctgaca acgatcggag 6180gaccgaagga gctaaccgct tttttgcaca acatggggga tcatgtaact cgccttgatc 6240gttgggaacc ggagctgaat gaagccatac caaacgacga gcgtgacacc acgatgcctg 6300tagcaatggc aacaacgttg cgcaaactat taactggcga actacttact ctagcttccc 6360ggcaacaatt aatagactgg atggaggcgg ataaagttgc aggaccactt ctgcgctcgg 6420cccttccggc tggctggttt attgctgata aatctggagc cggtgagcgt gggtctcgcg 6480gtatcattgc agcactgggg ccagatggta agccctcccg tatcgtagtt atctacacga 6540cggggagtca ggcaactatg gatgaacgaa atagacagat cgctgagata ggtgcctcac 6600tgattaagca ttggtaactg tcagaccaag tttactcata tatactttag attgatttaa 6660aacttcattt ttaatttaaa aggatctagg tgaagatcct ttttgataat ctcatgacca 6720aaatccctta acgtgagttt tcgttccact gagcgtcaga ccccgtagaa aagatcaaag 6780gatcttcttg agatcctttt tttctgcgcg taatctgctg cttgcaaaca aaaaaaccac 6840cgctaccagc ggtggtttgt ttgccggatc aagagctacc aactcttttt ccgaaggtaa 6900ctggcttcag cagagcgcag ataccaaata ctgttcttct agtgtagccg tagttaggcc 6960accacttcaa gaactctgta gcaccgccta catacctcgc tctgctaatc ctgttaccag 7020tggctgctgc cagtggcgat aagtcgtgtc ttaccgggtt ggactcaaga cgatagttac 7080cggataaggc gcagcggtcg ggctgaacgg ggggttcgtg cacacagccc agcttggagc 7140gaacgaccta caccgaactg agatacctac agcgtgagct atgagaaagc gccacgcttc 7200ccgaagggag aaaggcggac aggtatccgg taagcggcag ggtcggaaca ggagagcgca 7260cgagggagct tccaggggga aacgcctggt atctttatag tcctgtcggg tttcgccacc 7320tctgacttga gcgtcgattt ttgtgatgct cgtcaggggg gcggagccta tggaaaaacg 7380ccagcaacgc ggccttttta cggttcctgg ccttttgctg gccttttgct cacatgttct 7440ttcctgcgtt atcccctgat tctgtggata accgtattac cgcctttgag tgagctgata 7500ccgctcgccg cagccgaacg accgagcgca gcgagtcagt gagcgaggaa gcggaagagc 7560gcccaatacg caaaccgcct ctccccgcgc gttggccgat tcattaatgc agctggcacg 7620acaggtttcc cgactggaaa gcgggcagtg agcgcaacgc aattaatgtg agttagctca 7680ctcattaggc accccaggct ttacacttta tgcttccggc tcgtatgttg tgtggaattg 7740tgagcggata acaatttcac acaggaaaca gctatgacca tgattacgcc aagctcgaaa 7800ttaaccctca ctaaagggaa caaaagctgg agctccaccg cggtggcggc ctcgaggtcg 7860agatccggtc gaccagcaac catagtcccg cccctaactc cgcccatccc gcccctaact 7920ccgcccagtt ccgcccattc tccgccccat ggctgactaa ttttttttat ttatgcagag 7980gccgaggccg cctcggcctc tgagctattc cagaagtagt gaggaggctt ttttggaggc 8040ctaggctttt gcaaaaagct tcgacggtat cgattggctc atgtccaaca ttaccgccat 8100gttgacattg attattgact agttattaat agtaatcaat tacggggtca ttagttcata 8160gcccatatat ggagttccgc gttacataac ttacggtaaa tggcccgcct ggctgaccgc 8220ccaacgaccc ccgcccattg acgtcaataa tgacgtatgt tcccatagta acgccaatag 8280ggactttcca ttgacgtcaa tgggtggagt atttacggta aactgcccac ttggcagtac 8340atcaagtgta tcatatgcca agtacgcccc ctattgacgt caatgacggt aaatggcccg 8400cctggcatta tgcccagtac atgaccttat gggactttcc tacttggcag tacatctacg 8460tattagtcat cgctattacc atggtgatgc ggttttggca gtacatcaat gggcgtggat 8520agcggtttga ctcacgggga tttccaagtc tccaccccat tgacgtcaat gggagtttgt 8580tttggcacca aaatcaacgg gactttccaa aatgtcgtaa caactccgcc ccattgacgc 8640aaatgggcgg taggcgtgta cggaattcgg agtggcgagc cctcagatcc tgcatataag 8700cagctgcttt ttgcctgtac tgggtctctc tg 87321410PRTArtificial Sequencesource/note="Description of Artificial Sequence Synthetic peptide" 14Gly Gly Gly Ser Ser Gly Gly Gly Ser Gly1 5 101512PRTArtificial Sequencesource/note="Description of Artificial Sequence Synthetic peptide" 15Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro1 5 101622PRTArtificial Sequencesource/note="Description of Artificial Sequence Synthetic peptide" 16Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Gly Gly Gly Ser1 5 10 15Ser Gly Gly Gly Ser Gly 201739PRTArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polypeptide" 17Ile Glu Val Met Tyr Pro Pro Pro Tyr Leu Asp Asn Glu Lys Ser Asn1 5 10 15Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro Leu 20 25 30Phe Pro Gly Pro Ser Lys Pro 351848PRTArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polypeptide" 18Ala Lys Pro Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro1 5 10 15Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro 20 25 30Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp 35 40 451945PRTArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polypeptide" 19Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala1 5 10 15Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly 20 25 30Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp 35 40 4520129PRTArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polypeptide" 20Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Gly Gly Gly Ser1 5 10 15Ser Gly Gly Gly Ser Gly Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr 20 25 30Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr 35 40 45Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu 50 55 60Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu65 70 75 80Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys 85 90 95Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu 100 105 110Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly 115 120 125Lys2121PRTHomo sapiens 21Leu Cys Tyr Leu Leu Asp Gly Ile Leu Phe Ile Tyr Gly Val Ile Leu1 5 10 15Thr Ala Leu Phe Leu 202227PRTHomo sapiens 22Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu1 5 10 15Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val 20 252321PRTHomo sapiens 23Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu1 5 10 15Ser Leu Val Ile Thr 202423PRTHomo sapiens 24Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu1 5 10 15Ser Leu Val Ile Thr Leu Tyr 202524PRTHomo sapiens 25Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu1 5 10 15Ser Leu Val Ile Thr Leu Tyr Cys 202627PRTHomo sapiens 26Ile Ile Ser Phe Phe Leu Ala Leu Thr Ser Thr Ala Leu Leu Phe Leu1 5 10 15Leu Phe Phe Leu Thr Leu Arg Phe Ser Val Val 20 252741PRTHomo sapiens 27Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr1 5 10 15Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro 20 25 30Pro Arg Asp Phe Ala Ala Tyr Arg Ser 35 402841PRTHomo sapiens 28Arg Ser Lys Arg Ser Arg Gly Gly His Ser Asp Tyr Met Asn Met Thr1 5 10 15Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro 20 25 30Pro Arg Asp Phe Ala Ala Tyr Arg Ser 35 402942PRTHomo sapiens 29Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met1 5 10 15Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe 20 25 30Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu 35 403042PRTHomo sapiens 30Ala Leu Tyr Leu Leu Arg Arg Asp Gln Arg Leu Pro Pro Asp Ala His1 5 10 15Lys Pro Pro Gly Gly Gly Ser Phe Arg Thr Pro Ile Gln Glu Glu Gln 20 25 30Ala Asp Ala His Ser Thr Leu Ala Lys Ile 35 4031362PRTArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polypeptide" 31Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro1 5 10 15Ala Phe Leu Leu Ile Pro Gly Pro Val Pro Pro Ser Thr Ala Leu Arg 20 25 30Tyr Leu Ile Glu Glu Leu Val Asn Ile Thr Gln Asn Gln Lys Ala Pro 35 40 45Leu Cys Asn Gly Ser Met Val Trp Ser Ile Asn Leu Thr Ala Gly Met 50 55 60Tyr Cys Ala Ala Leu Glu Ser Leu Ile Asn Val Ser Gly Cys Ser Ala65 70 75 80Ile Glu Lys Thr Gln Arg Met Leu Ser Gly Phe Cys Pro His Lys Val 85 90 95Ser Ala Gly Gln Phe Ser Ser Leu His Val Arg Asp Thr Lys Ile Glu 100 105 110Val Ala Gln Phe Val Lys Asp Leu Leu Leu His Leu Lys Lys Leu Phe 115 120 125Arg Glu Gly Arg Phe Asn Ala Lys Pro Thr Thr Thr Pro Ala Pro Arg 130 135 140Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg145 150 155 160Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly 165 170 175Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr 180 185 190Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Lys Arg Gly 195 200 205Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val 210 215 220Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu225 230 235 240Glu Glu Gly Gly Cys Glu Leu Gly Gly Gly Arg Val Lys Phe Ser Arg 245 250 255Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn 260 265 270Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg 275 280 285Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro 290 295 300Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala305 310 315 320Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His 325 330 335Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp 340 345 350Ala Leu His Met Gln Ala Leu Pro Pro Arg 355 36032410PRTArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polypeptide" 32Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro1 5 10 15Ala Phe Leu Leu Ile Pro Gly Pro Val Pro Pro Ser Thr Ala Leu Arg 20 25 30Tyr Leu Ile Glu Glu Leu Val Asn Ile Thr Gln Asn Gln Lys Ala Pro 35 40 45Leu Cys Asn Gly Ser Met Val Trp Ser Ile Asn Leu Thr Ala Gly Met 50 55 60Tyr Cys Ala Ala Leu Glu Ser Leu Ile Asn Val Ser Gly Cys Ser Ala65 70 75 80Ile Glu Lys Thr Gln Arg Met Leu Ser Gly Phe Cys Pro His Lys Val 85 90 95Ser Ala Gly Gln Phe Ser Ser Leu His Val Arg Asp Thr Lys Ile Glu 100 105 110Val Ala Gln Phe Val Lys Asp Leu Leu Leu His Leu Lys Lys Leu Phe 115 120 125Arg Glu Gly Arg Phe Asn Ala Lys Pro Thr Thr Thr Pro Ala Pro Arg 130 135 140Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg145 150 155 160Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly 165 170 175Leu Asp Phe Ala Cys Asp Phe Trp Val Leu Val Val Val Gly Gly Val 180 185 190Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp 195 200 205Val Arg Ser Lys Arg Ser Arg Gly Gly His Ser Asp Tyr Met Asn Met 210 215 220Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala225 230 235 240Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Gly Gly Gly Lys Arg Gly 245 250 255Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val 260 265 270Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu 275 280 285Glu Glu Gly Gly Cys Glu Leu Gly Gly Gly Arg Val Lys Phe Ser Arg 290 295 300Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn305 310 315 320Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg 325 330 335Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro 340 345 350Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala 355 360 365Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His 370 375 380Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp385 390 395 400Ala Leu His Met Gln Ala Leu Pro Pro Arg 405 41033442PRTArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polypeptide" 33Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro1 5 10 15Ala Phe Leu Leu Ile Pro Gly Pro Val Pro Pro Ser Thr Ala Leu Arg 20 25 30Tyr Leu Ile Glu Glu Leu Val Asn Ile Thr Gln Asn Gln Lys Ala Pro 35 40 45Leu Cys Asn Gly Ser Met Val Trp Ser Ile Asn Leu Thr Ala Gly Met 50 55 60Tyr Cys Ala Ala Leu Glu Ser Leu Ile Asn Val Ser Gly Cys Ser Ala65 70 75 80Ile Glu Lys Thr Gln Arg Met Leu Ser Gly Phe Cys Pro His Lys Val 85 90 95Ser Ala Gly Gln Phe Ser Ser Leu His Val Arg Asp Thr Lys Ile Glu 100 105 110Val Ala Gln Phe Val Lys Asp Leu Leu Leu His Leu Lys Lys Leu Phe 115 120 125Arg Glu Gly Arg Phe Asn Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro 130 135 140Cys Pro Gly Gly Gly Ser Ser Gly Gly Gly Ser Gly Gly Gln Pro Arg145 150 155 160Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys 165 170 175Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 180 185 190Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 195 200 205Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 210 215 220Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser225 230 235 240Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser 245

250 255Leu Ser Leu Ser Leu Gly Lys Met Ala Leu Ile Val Leu Gly Gly Val 260 265 270Ala Gly Leu Leu Leu Phe Ile Gly Leu Gly Ile Phe Phe Lys Arg Gly 275 280 285Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val 290 295 300Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu305 310 315 320Glu Glu Gly Gly Cys Glu Leu Gly Gly Gly Arg Val Lys Phe Ser Arg 325 330 335Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn 340 345 350Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg 355 360 365Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro 370 375 380Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala385 390 395 400Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His 405 410 415Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp 420 425 430Ala Leu His Met Gln Ala Leu Pro Pro Arg 435 44034541PRTArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polypeptide" 34Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro1 5 10 15Ala Phe Leu Leu Ile Pro Gly Pro Val Pro Pro Ser Thr Ala Leu Arg 20 25 30Tyr Leu Ile Glu Glu Leu Val Asn Ile Thr Gln Asn Gln Lys Ala Pro 35 40 45Leu Cys Asn Gly Ser Met Val Trp Ser Ile Asn Leu Thr Ala Gly Met 50 55 60Tyr Cys Ala Ala Leu Glu Ser Leu Ile Asn Val Ser Gly Cys Ser Ala65 70 75 80Ile Glu Lys Thr Gln Arg Met Leu Ser Gly Phe Cys Pro His Lys Val 85 90 95Ser Ala Gly Gln Phe Ser Ser Leu His Val Arg Asp Thr Lys Ile Glu 100 105 110Val Ala Gln Phe Val Lys Asp Leu Leu Leu His Leu Lys Lys Leu Phe 115 120 125Arg Glu Gly Arg Phe Asn Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro 130 135 140Cys Pro Ala Pro Glu Phe Glu Gly Gly Pro Ser Val Phe Leu Phe Pro145 150 155 160Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr 165 170 175Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn 180 185 190Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg 195 200 205Glu Glu Gln Phe Gln Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val 210 215 220Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser225 230 235 240Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys 245 250 255Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu 260 265 270Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe 275 280 285Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu 290 295 300Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe305 310 315 320Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly 325 330 335Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr 340 345 350Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys Ile Tyr Ile Trp Ala 355 360 365Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr 370 375 380Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met385 390 395 400Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe 405 410 415Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Gly Gly Gly Arg Val Lys 420 425 430Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln 435 440 445Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu 450 455 460Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg465 470 475 480Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met 485 490 495Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly 500 505 510Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp 515 520 525Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg 530 535 54035373PRTArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polypeptide" 35Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro1 5 10 15Ala Phe Leu Leu Ile Pro Gly Pro Val Pro Pro Ser Thr Ala Leu Arg 20 25 30Tyr Leu Ile Glu Glu Leu Val Asn Ile Thr Gln Asn Gln Lys Ala Pro 35 40 45Leu Cys Asn Gly Ser Met Val Trp Ser Ile Asn Leu Thr Ala Gly Met 50 55 60Tyr Cys Ala Ala Leu Glu Ser Leu Ile Asn Val Ser Gly Cys Ser Ala65 70 75 80Ile Glu Lys Thr Gln Arg Met Leu Ser Gly Phe Cys Pro His Lys Val 85 90 95Ser Ala Gly Gln Phe Ser Ser Leu His Val Arg Asp Thr Lys Ile Glu 100 105 110Val Ala Gln Phe Val Lys Asp Leu Leu Leu His Leu Lys Lys Leu Phe 115 120 125Arg Glu Gly Arg Phe Asn Gly Gly Gly Ser Ser Gly Gly Gly Ser Gly 130 135 140Met Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser145 150 155 160Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg 165 170 175Ser Arg Gly Gly His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro 180 185 190Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe 195 200 205Ala Ala Tyr Arg Ser Gly Gly Gly Lys Arg Gly Arg Lys Lys Leu Leu 210 215 220Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu225 230 235 240Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys 245 250 255Glu Leu Gly Gly Gly Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro 260 265 270Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly 275 280 285Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro 290 295 300Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr305 310 315 320Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly 325 330 335Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln 340 345 350Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln 355 360 365Ala Leu Pro Pro Arg 37036385PRTArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polypeptide" 36Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro1 5 10 15Ala Phe Leu Leu Ile Pro Gly Pro Val Pro Pro Ser Thr Ala Leu Arg 20 25 30Tyr Leu Ile Glu Glu Leu Val Asn Ile Thr Gln Asn Gln Lys Ala Pro 35 40 45Leu Cys Asn Gly Ser Met Val Trp Ser Ile Asn Leu Thr Ala Gly Met 50 55 60Tyr Cys Ala Ala Leu Glu Ser Leu Ile Asn Val Ser Gly Cys Ser Ala65 70 75 80Ile Glu Lys Thr Gln Arg Met Leu Ser Gly Phe Cys Pro His Lys Val 85 90 95Ser Ala Gly Gln Phe Ser Ser Leu His Val Arg Asp Thr Lys Ile Glu 100 105 110Val Ala Gln Phe Val Lys Asp Leu Leu Leu His Leu Lys Lys Leu Phe 115 120 125Arg Glu Gly Arg Phe Asn Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro 130 135 140Cys Pro Gly Gly Gly Ser Ser Gly Gly Gly Ser Gly Met Phe Trp Val145 150 155 160Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr 165 170 175Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg Gly Gly 180 185 190His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg 195 200 205Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg 210 215 220Ser Gly Gly Gly Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys225 230 235 240Gln Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys 245 250 255Ser Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Gly Gly 260 265 270Gly Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln 275 280 285Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu 290 295 300Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly305 310 315 320Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln 325 330 335Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu 340 345 350Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr 355 360 365Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro 370 375 380Arg38537492PRTArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polypeptide" 37Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro1 5 10 15Ala Phe Leu Leu Ile Pro Gly Pro Val Pro Pro Ser Thr Ala Leu Arg 20 25 30Tyr Leu Ile Glu Glu Leu Val Asn Ile Thr Gln Asn Gln Lys Ala Pro 35 40 45Leu Cys Asn Gly Ser Met Val Trp Ser Ile Asn Leu Thr Ala Gly Met 50 55 60Tyr Cys Ala Ala Leu Glu Ser Leu Ile Asn Val Ser Gly Cys Ser Ala65 70 75 80Ile Glu Lys Thr Gln Arg Met Leu Ser Gly Phe Cys Pro His Lys Val 85 90 95Ser Ala Gly Gln Phe Ser Ser Leu His Val Arg Asp Thr Lys Ile Glu 100 105 110Val Ala Gln Phe Val Lys Asp Leu Leu Leu His Leu Lys Lys Leu Phe 115 120 125Arg Glu Gly Arg Phe Asn Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro 130 135 140Cys Pro Gly Gly Gly Ser Ser Gly Gly Gly Ser Gly Gly Gln Pro Arg145 150 155 160Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys 165 170 175Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 180 185 190Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 195 200 205Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 210 215 220Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser225 230 235 240Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser 245 250 255Leu Ser Leu Ser Leu Gly Lys Met Phe Trp Val Leu Val Val Val Gly 260 265 270Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile 275 280 285Phe Trp Val Arg Ser Lys Arg Ser Arg Gly Gly His Ser Asp Tyr Met 290 295 300Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro305 310 315 320Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Gly Gly Gly Lys 325 330 335Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg 340 345 350Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro 355 360 365Glu Glu Glu Glu Gly Gly Cys Glu Leu Gly Gly Gly Arg Val Lys Phe 370 375 380Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu385 390 395 400Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp 405 410 415Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys 420 425 430Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala 435 440 445Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys 450 455 460Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr465 470 475 480Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg 485 49038592PRTArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polypeptide" 38Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro1 5 10 15Ala Phe Leu Leu Ile Pro Gly Pro Val Pro Pro Ser Thr Ala Leu Arg 20 25 30Tyr Leu Ile Glu Glu Leu Val Asn Ile Thr Gln Asn Gln Lys Ala Pro 35 40 45Leu Cys Asn Gly Ser Met Val Trp Ser Ile Asn Leu Thr Ala Gly Met 50 55 60Tyr Cys Ala Ala Leu Glu Ser Leu Ile Asn Val Ser Gly Cys Ser Ala65 70 75 80Ile Glu Lys Thr Gln Arg Met Leu Ser Gly Phe Cys Pro His Lys Val 85 90 95Ser Ala Gly Gln Phe Ser Ser Leu His Val Arg Asp Thr Lys Ile Glu 100 105 110Val Ala Gln Phe Val Lys Asp Leu Leu Leu His Leu Lys Lys Leu Phe 115 120 125Arg Glu Gly Arg Phe Asn Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro 130 135 140Cys Pro Ala Pro Glu Phe Glu Gly Gly Pro Ser Val Phe Leu Phe Pro145 150 155 160Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr 165 170 175Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn 180 185 190Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg 195 200 205Glu Glu Gln Phe Gln Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val 210 215 220Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser225 230 235 240Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys 245 250 255Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu 260 265 270Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe 275 280 285Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu 290 295 300Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe305 310 315 320Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly 325 330 335Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr 340 345 350Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys Met Phe Trp Val Leu 355 360 365Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val 370 375 380Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg Gly Gly His385 390 395 400Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys 405 410 415His Tyr Gln Pro Tyr

Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser 420 425 430Gly Gly Gly Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln 435 440 445Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser 450 455 460Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Gly Gly Gly465 470 475 480Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly 485 490 495Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr 500 505 510Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys 515 520 525Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys 530 535 540Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg545 550 555 560Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala 565 570 575Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg 580 585 59039340PRTArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polypeptide" 39Gly Pro Val Pro Pro Ser Thr Ala Leu Arg Tyr Leu Ile Glu Glu Leu1 5 10 15Val Asn Ile Thr Gln Asn Gln Lys Ala Pro Leu Cys Asn Gly Ser Met 20 25 30Val Trp Ser Ile Asn Leu Thr Ala Gly Met Tyr Cys Ala Ala Leu Glu 35 40 45Ser Leu Ile Asn Val Ser Gly Cys Ser Ala Ile Glu Lys Thr Gln Arg 50 55 60Met Leu Ser Gly Phe Cys Pro His Lys Val Ser Ala Gly Gln Phe Ser65 70 75 80Ser Leu His Val Arg Asp Thr Lys Ile Glu Val Ala Gln Phe Val Lys 85 90 95Asp Leu Leu Leu His Leu Lys Lys Leu Phe Arg Glu Gly Arg Phe Asn 100 105 110Ala Lys Pro Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro 115 120 125Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro 130 135 140Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp145 150 155 160Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu 165 170 175Ser Leu Val Ile Thr Leu Tyr Lys Arg Gly Arg Lys Lys Leu Leu Tyr 180 185 190Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu 195 200 205Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu 210 215 220Leu Gly Gly Gly Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala225 230 235 240Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg 245 250 255Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu 260 265 270Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn 275 280 285Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met 290 295 300Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly305 310 315 320Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala 325 330 335Leu Pro Pro Arg 34040388PRTArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polypeptide" 40Gly Pro Val Pro Pro Ser Thr Ala Leu Arg Tyr Leu Ile Glu Glu Leu1 5 10 15Val Asn Ile Thr Gln Asn Gln Lys Ala Pro Leu Cys Asn Gly Ser Met 20 25 30Val Trp Ser Ile Asn Leu Thr Ala Gly Met Tyr Cys Ala Ala Leu Glu 35 40 45Ser Leu Ile Asn Val Ser Gly Cys Ser Ala Ile Glu Lys Thr Gln Arg 50 55 60Met Leu Ser Gly Phe Cys Pro His Lys Val Ser Ala Gly Gln Phe Ser65 70 75 80Ser Leu His Val Arg Asp Thr Lys Ile Glu Val Ala Gln Phe Val Lys 85 90 95Asp Leu Leu Leu His Leu Lys Lys Leu Phe Arg Glu Gly Arg Phe Asn 100 105 110Ala Lys Pro Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro 115 120 125Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro 130 135 140Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp145 150 155 160Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu 165 170 175Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser 180 185 190Arg Gly Gly His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly 195 200 205Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala 210 215 220Ala Tyr Arg Ser Gly Gly Gly Lys Arg Gly Arg Lys Lys Leu Leu Tyr225 230 235 240Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu 245 250 255Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu 260 265 270Leu Gly Gly Gly Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala 275 280 285Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg 290 295 300Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu305 310 315 320Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn 325 330 335Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met 340 345 350Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly 355 360 365Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala 370 375 380Leu Pro Pro Arg38541420PRTArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polypeptide" 41Gly Pro Val Pro Pro Ser Thr Ala Leu Arg Tyr Leu Ile Glu Glu Leu1 5 10 15Val Asn Ile Thr Gln Asn Gln Lys Ala Pro Leu Cys Asn Gly Ser Met 20 25 30Val Trp Ser Ile Asn Leu Thr Ala Gly Met Tyr Cys Ala Ala Leu Glu 35 40 45Ser Leu Ile Asn Val Ser Gly Cys Ser Ala Ile Glu Lys Thr Gln Arg 50 55 60Met Leu Ser Gly Phe Cys Pro His Lys Val Ser Ala Gly Gln Phe Ser65 70 75 80Ser Leu His Val Arg Asp Thr Lys Ile Glu Val Ala Gln Phe Val Lys 85 90 95Asp Leu Leu Leu His Leu Lys Lys Leu Phe Arg Glu Gly Arg Phe Asn 100 105 110Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Gly Gly Gly Ser 115 120 125Ser Gly Gly Gly Ser Gly Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr 130 135 140Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr145 150 155 160Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu 165 170 175Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu 180 185 190Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys 195 200 205Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu 210 215 220Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly225 230 235 240Lys Met Ala Leu Ile Val Leu Gly Gly Val Ala Gly Leu Leu Leu Phe 245 250 255Ile Gly Leu Gly Ile Phe Phe Lys Arg Gly Arg Lys Lys Leu Leu Tyr 260 265 270Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu 275 280 285Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu 290 295 300Leu Gly Gly Gly Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala305 310 315 320Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg 325 330 335Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu 340 345 350Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn 355 360 365Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met 370 375 380Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly385 390 395 400Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala 405 410 415Leu Pro Pro Arg 42042519PRTArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polypeptide" 42Gly Pro Val Pro Pro Ser Thr Ala Leu Arg Tyr Leu Ile Glu Glu Leu1 5 10 15Val Asn Ile Thr Gln Asn Gln Lys Ala Pro Leu Cys Asn Gly Ser Met 20 25 30Val Trp Ser Ile Asn Leu Thr Ala Gly Met Tyr Cys Ala Ala Leu Glu 35 40 45Ser Leu Ile Asn Val Ser Gly Cys Ser Ala Ile Glu Lys Thr Gln Arg 50 55 60Met Leu Ser Gly Phe Cys Pro His Lys Val Ser Ala Gly Gln Phe Ser65 70 75 80Ser Leu His Val Arg Asp Thr Lys Ile Glu Val Ala Gln Phe Val Lys 85 90 95Asp Leu Leu Leu His Leu Lys Lys Leu Phe Arg Glu Gly Arg Phe Asn 100 105 110Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe 115 120 125Glu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 130 135 140Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val145 150 155 160Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val 165 170 175Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Gln Ser 180 185 190Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 195 200 205Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser 210 215 220Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro225 230 235 240Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln 245 250 255Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 260 265 270Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 275 280 285Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu 290 295 300Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser305 310 315 320Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 325 330 335Leu Ser Leu Gly Lys Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys 340 345 350Gly Val Leu Leu Leu Ser Leu Val Ile Thr Lys Arg Gly Arg Lys Lys 355 360 365Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln Thr Thr 370 375 380Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu Gly385 390 395 400Gly Cys Glu Leu Gly Gly Gly Arg Val Lys Phe Ser Arg Ser Ala Asp 405 410 415Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn 420 425 430Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg 435 440 445Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly 450 455 460Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu465 470 475 480Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu 485 490 495Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His 500 505 510Met Gln Ala Leu Pro Pro Arg 51543351PRTArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polypeptide" 43Gly Pro Val Pro Pro Ser Thr Ala Leu Arg Tyr Leu Ile Glu Glu Leu1 5 10 15Val Asn Ile Thr Gln Asn Gln Lys Ala Pro Leu Cys Asn Gly Ser Met 20 25 30Val Trp Ser Ile Asn Leu Thr Ala Gly Met Tyr Cys Ala Ala Leu Glu 35 40 45Ser Leu Ile Asn Val Ser Gly Cys Ser Ala Ile Glu Lys Thr Gln Arg 50 55 60Met Leu Ser Gly Phe Cys Pro His Lys Val Ser Ala Gly Gln Phe Ser65 70 75 80Ser Leu His Val Arg Asp Thr Lys Ile Glu Val Ala Gln Phe Val Lys 85 90 95Asp Leu Leu Leu His Leu Lys Lys Leu Phe Arg Glu Gly Arg Phe Asn 100 105 110Gly Gly Gly Ser Ser Gly Gly Gly Ser Gly Met Phe Trp Val Leu Val 115 120 125Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala 130 135 140Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg Gly Gly His Ser145 150 155 160Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His 165 170 175Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Gly 180 185 190Gly Gly Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro 195 200 205Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys 210 215 220Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Gly Gly Gly Arg225 230 235 240Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln 245 250 255Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp 260 265 270Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro 275 280 285Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp 290 295 300Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg305 310 315 320Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr 325 330 335Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg 340 345 35044363PRTArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polypeptide" 44Gly Pro Val Pro Pro Ser Thr Ala Leu Arg Tyr Leu Ile Glu Glu Leu1 5 10 15Val Asn Ile Thr Gln Asn Gln Lys Ala Pro Leu Cys Asn Gly Ser Met 20 25 30Val Trp Ser Ile Asn Leu Thr Ala Gly Met Tyr Cys Ala Ala Leu Glu 35 40 45Ser Leu Ile Asn Val Ser Gly Cys Ser Ala Ile Glu Lys Thr Gln Arg 50 55 60Met Leu Ser Gly Phe Cys Pro His Lys Val Ser Ala Gly Gln Phe Ser65 70 75 80Ser Leu His Val Arg Asp Thr Lys Ile Glu Val Ala Gln Phe Val Lys 85 90 95Asp Leu Leu Leu His Leu Lys Lys Leu Phe Arg Glu Gly Arg Phe Asn 100 105 110Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Gly Gly Gly Ser 115 120 125Ser Gly Gly Gly Ser Gly Met Phe Trp Val Leu Val Val Val Gly Gly 130 135 140Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile Phe145 150 155 160Trp Val Arg Ser Lys Arg Ser Arg Gly Gly His Ser Asp Tyr Met Asn 165 170 175Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr 180 185 190Ala Pro Pro Arg Asp Phe

Ala Ala Tyr Arg Ser Gly Gly Gly Lys Arg 195 200 205Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro 210 215 220Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu225 230 235 240Glu Glu Glu Gly Gly Cys Glu Leu Gly Gly Gly Arg Val Lys Phe Ser 245 250 255Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr 260 265 270Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys 275 280 285Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn 290 295 300Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu305 310 315 320Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly 325 330 335His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr 340 345 350Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg 355 36045470PRTArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polypeptide" 45Gly Pro Val Pro Pro Ser Thr Ala Leu Arg Tyr Leu Ile Glu Glu Leu1 5 10 15Val Asn Ile Thr Gln Asn Gln Lys Ala Pro Leu Cys Asn Gly Ser Met 20 25 30Val Trp Ser Ile Asn Leu Thr Ala Gly Met Tyr Cys Ala Ala Leu Glu 35 40 45Ser Leu Ile Asn Val Ser Gly Cys Ser Ala Ile Glu Lys Thr Gln Arg 50 55 60Met Leu Ser Gly Phe Cys Pro His Lys Val Ser Ala Gly Gln Phe Ser65 70 75 80Ser Leu His Val Arg Asp Thr Lys Ile Glu Val Ala Gln Phe Val Lys 85 90 95Asp Leu Leu Leu His Leu Lys Lys Leu Phe Arg Glu Gly Arg Phe Asn 100 105 110Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Gly Gly Gly Ser 115 120 125Ser Gly Gly Gly Ser Gly Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr 130 135 140Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr145 150 155 160Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu 165 170 175Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu 180 185 190Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys 195 200 205Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu 210 215 220Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly225 230 235 240Lys Met Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr 245 250 255Ser Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys 260 265 270Arg Ser Arg Gly Gly His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg 275 280 285Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp 290 295 300Phe Ala Ala Tyr Arg Ser Gly Gly Gly Lys Arg Gly Arg Lys Lys Leu305 310 315 320Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln Thr Thr Gln 325 330 335Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly 340 345 350Cys Glu Leu Gly Gly Gly Arg Val Lys Phe Ser Arg Ser Ala Asp Ala 355 360 365Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu 370 375 380Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp385 390 395 400Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu 405 410 415Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile 420 425 430Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr 435 440 445Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met 450 455 460Gln Ala Leu Pro Pro Arg465 47046570PRTArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polypeptide" 46Gly Pro Val Pro Pro Ser Thr Ala Leu Arg Tyr Leu Ile Glu Glu Leu1 5 10 15Val Asn Ile Thr Gln Asn Gln Lys Ala Pro Leu Cys Asn Gly Ser Met 20 25 30Val Trp Ser Ile Asn Leu Thr Ala Gly Met Tyr Cys Ala Ala Leu Glu 35 40 45Ser Leu Ile Asn Val Ser Gly Cys Ser Ala Ile Glu Lys Thr Gln Arg 50 55 60Met Leu Ser Gly Phe Cys Pro His Lys Val Ser Ala Gly Gln Phe Ser65 70 75 80Ser Leu His Val Arg Asp Thr Lys Ile Glu Val Ala Gln Phe Val Lys 85 90 95Asp Leu Leu Leu His Leu Lys Lys Leu Phe Arg Glu Gly Arg Phe Asn 100 105 110Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe 115 120 125Glu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 130 135 140Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val145 150 155 160Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val 165 170 175Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Gln Ser 180 185 190Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 195 200 205Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser 210 215 220Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro225 230 235 240Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln 245 250 255Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 260 265 270Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 275 280 285Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu 290 295 300Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser305 310 315 320Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 325 330 335Leu Ser Leu Gly Lys Met Phe Trp Val Leu Val Val Val Gly Gly Val 340 345 350Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp 355 360 365Val Arg Ser Lys Arg Ser Arg Gly Gly His Ser Asp Tyr Met Asn Met 370 375 380Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala385 390 395 400Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Gly Gly Gly Lys Arg Gly 405 410 415Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val 420 425 430Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu 435 440 445Glu Glu Gly Gly Cys Glu Leu Gly Gly Gly Arg Val Lys Phe Ser Arg 450 455 460Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn465 470 475 480Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg 485 490 495Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro 500 505 510Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala 515 520 525Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His 530 535 540Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp545 550 555 560Ala Leu His Met Gln Ala Leu Pro Pro Arg 565 57047363PRTArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polypeptide" 47Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro1 5 10 15Ala Phe Leu Leu Ile Pro Gly Pro Val Pro Pro Ser Thr Ala Leu Arg 20 25 30Tyr Leu Ile Glu Glu Leu Val Asn Ile Thr Gln Asn Gln Lys Ala Pro 35 40 45Leu Cys Asn Gly Ser Met Val Trp Ser Ile Asn Leu Thr Ala Gly Met 50 55 60Tyr Cys Ala Ala Leu Glu Ser Leu Ile Asn Val Ser Gly Cys Ser Ala65 70 75 80Ile Glu Lys Thr Gln Arg Met Leu Ser Gly Phe Cys Pro His Lys Val 85 90 95Ser Ala Gly Gln Phe Ser Ser Leu His Val Arg Asp Thr Lys Ile Glu 100 105 110Val Ala Gln Phe Val Lys Asp Leu Leu Leu His Leu Lys Lys Leu Phe 115 120 125Arg Glu Gly Arg Phe Asn Ala Lys Pro Thr Thr Thr Pro Ala Pro Arg 130 135 140Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg145 150 155 160Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly 165 170 175Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr 180 185 190Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Gly Gly Gly Lys Arg 195 200 205Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro 210 215 220Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu225 230 235 240Glu Glu Glu Gly Gly Cys Glu Leu Gly Gly Gly Arg Val Lys Phe Ser 245 250 255Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr 260 265 270Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys 275 280 285Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn 290 295 300Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu305 310 315 320Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly 325 330 335His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr 340 345 350Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg 355 36048341PRTArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polypeptide" 48Gly Pro Val Pro Pro Ser Thr Ala Leu Arg Tyr Leu Ile Glu Glu Leu1 5 10 15Val Asn Ile Thr Gln Asn Gln Lys Ala Pro Leu Cys Asn Gly Ser Met 20 25 30Val Trp Ser Ile Asn Leu Thr Ala Gly Met Tyr Cys Ala Ala Leu Glu 35 40 45Ser Leu Ile Asn Val Ser Gly Cys Ser Ala Ile Glu Lys Thr Gln Arg 50 55 60Met Leu Ser Gly Phe Cys Pro His Lys Val Ser Ala Gly Gln Phe Ser65 70 75 80Ser Leu His Val Arg Asp Thr Lys Ile Glu Val Ala Gln Phe Val Lys 85 90 95Asp Leu Leu Leu His Leu Lys Lys Leu Phe Arg Glu Gly Arg Phe Asn 100 105 110Ala Lys Pro Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro 115 120 125Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro 130 135 140Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp145 150 155 160Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu 165 170 175Ser Leu Val Ile Thr Gly Gly Gly Lys Arg Gly Arg Lys Lys Leu Leu 180 185 190Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu 195 200 205Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys 210 215 220Glu Leu Gly Gly Gly Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro225 230 235 240Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly 245 250 255Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro 260 265 270Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr 275 280 285Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly 290 295 300Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln305 310 315 320Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln 325 330 335Ala Leu Pro Pro Arg 34049112PRTHomo sapiens 49Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly1 5 10 15Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr 20 25 30Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys 35 40 45Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys 50 55 60Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg65 70 75 80Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala 85 90 95Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg 100 105 11050107PRTArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polypeptide" 50Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu1 5 10 15Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe 20 25 30Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu 35 40 45Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe 50 55 60Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly65 70 75 80Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr 85 90 95Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys 100 10551229PRTArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polypeptide" 51Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe1 5 10 15Glu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 20 25 30Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 35 40 45Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val 50 55 60Glu Val His Gln Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser65 70 75 80Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 85 90 95Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser 100 105 110Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 115 120 125Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln 130 135 140Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala145 150 155 160Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 165 170 175Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu 180 185 190Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser 195 200 205Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 210 215 220Leu Ser Leu Gly Lys2255212PRTArtificial Sequencesource/note="Description of Artificial Sequence Synthetic peptide" 52Glu Ser Lys Tyr Gly Pro Pro Cys Pro Ser Cys Pro1

5 1053229PRTArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polypeptide" 53Glu Ser Lys Tyr Gly Pro Pro Cys Pro Ser Cys Pro Ala Pro Glu Phe1 5 10 15Glu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 20 25 30Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 35 40 45Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val 50 55 60Glu Val His Gln Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser65 70 75 80Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 85 90 95Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser 100 105 110Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 115 120 125Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln 130 135 140Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala145 150 155 160Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 165 170 175Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu 180 185 190Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser 195 200 205Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 210 215 220Leu Ser Leu Gly Lys2255428PRTHomo sapiens 54Met Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser1 5 10 15Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val 20 25

Claims

1. A population of human T cells transduced by a vector comprising an expression cassette encoding a chimeric antigen receptor, wherein chimeric antigen receptor comprises: a human IL-13 variant comprising the amino acid sequence of SEQ ID NO: 3 with up to 5 single amino acid substitutions, provided that the amino acid at position 11 of SEQ ID NO: 3 other than E; a transmembrane domain selected from: a CD4 transmembrane domain or variant thereof having 1-5 amino acid substations, a CD8 transmembrane domain or variant thereof having 1-5 amino acid substitutions, a CD28 transmembrane domain or a variant thereof having 1-5 amino acid substations, and a CD3 transmembrane domain or a variant thereof having 1-5 amino acid substitutions; a costimulatory domain selected from the group consisting of: a CD28 costimulatory domain or a variant thereof having 1-5 amino acid substitutions, a 4IBB costimulatory domain or a variant thereof having 1-5 amino acid substitutions and an OX40 costimulatory domain or a variant thereof having 1-5 amino acid substitutions; and CD3 .zeta. signaling domain of a variant thereof having 1-5 amino acid substitutions.

2. The population of human T cells of claim 1, wherein the chimeric antigen receptor comprising an amino acid sequence selected from SEQ ID NOs: 10, 31-48 and 52.

3. The population of human T cells of claim 1, wherein the chimeric antigen receptor comprises SEQ ID NO: 10.

4. A composition comprising T cells harboring a nucleic acid molecule comprising a nucleotide sequence encoding a chimeric antigen receptor molecule comprising the amino acid sequence of SEQ ID NO: 10.

5. A composition of comprising T cells harboring an expression vector comprising a nucleotide sequence encoding a chimeric antigen receptor molecule comprising the amino acid sequence of SEQ ID NO: 10.

6. The composition of claim 5, wherein the expression vector is a lentiviral vector.

7. The composition of claim 4, wherein the nucleic acid molecule further comprises a nucleotide sequence encoding a GMSCFRa signal sequence preceding the nucleotide sequence encoding the chimeric antigen receptor.

8. The composition of claim 7, wherein the GMSCFRa signal sequence comprises the amino acid sequence of SEQ ID NO:2.

9. The composition of claim 4, wherein the nucleic acid molecule further comprises a nucleotide sequence encoding a T2A ribosome skip sequence following the nucleotide sequence encoding the chimeric antigen receptor.

10. The composition of claim 9, wherein T2A ribosome skip sequence comprises the amino acid sequence of SEQ ID NO:8.

11. The composition of claim 9, wherein the nucleic acid molecule further comprises a nucleotide sequence encoding a truncated CD19 following the nucleotide sequence encoding the T2A ribosome skip sequence.

12. The composition of claim 10, wherein the truncated CD19 comprises the amino acid sequence of SEQ ID NO:9.

13. The composition of claim 5, wherein the T cells comprise central memory T cells.